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Abstract
In this thesis, we investigate the improvement in treatment effectiveness when dynam-
ically optimizing the fractionation scheme in radiation therapy.
In the first part of the thesis, we consider delivering a different dose each day de-
pending on the observed patient anatomy. Given that a fixed prescribed dose must be
delivered to the tumor over the course of the treatment, such an approach results in a
lower cumulative dose to a radio-sensitive organ-at-risk when compared to that result-
ing from standard fractionation. We use the dynamic programming algorithm to solve
the problem exactly. Next, we suggest an approach which optimizes the fraction size
and selects a treatment plan from a plan library. Computational results from patient
datasets indicate this approach is beneficial.
In the second part of the thesis, we analyze the effect of repopulation on the optimal
fractionation scheme. A dynamic programming framework is developed to determine
an optimal fractionation scheme based on a model of cell kill due to radiation and
tumor growth in between treatment days. We prove that the optimal dose fractions
are increasing over time. We find that the presence of accelerated tumor repopulation
suggests larger dose fractions later in the treatment to compensate for the increased
tumor proliferation.
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Chapter 1
Introduction
Things alter for the worse
spontaneously, if they be not
altered for the better designedly.
Sir Francis Bacon
1.1 Motivation
This thesis deals with dynamic optimization in radiation therapy. Conventional radia-
tion therapy procedures deliver an equal dose to the tumor every day over the course
of 30-40 days. The spatial and temporal dose distribution is optimized assuming the
patient anatomy is static over the course of treatment. Yet, due to uncertainties in the
daily patient setup as well as motion, among other reasons, radiation-sensitive organs
near the tumor can get exposed to high radiation doses, which could result in acute
or late side-effects. Furthermore, treatment planning procedures barely account for
temporal effects, such as tumor growth and shrinkage, and radiation response. In this
thesis, we seek to understand, both qualitatively and quantitatively, the improvement
in treatment effectiveness that can result from dynamic adaptation of the fractionation
scheme, i.e., the total number of treatment days and dose delivered per day.
One way to adapt doses and treatments is to make use of information acquired
15
between fractions (or treatment days). Such adaptation is becoming technologically
feasible because of improved imaging and information acquisition technologies. This
type of treatment modification, known as adaptive radiation therapy (ART), permits
customized day-to-day dose delivery to mitigate uncertainty in organ motion and/or
patient setup. The question arises as to whether adapting the fraction size based
on an acquired image of the patient anatomy immediately before delivery can improve
treatment outcome. If so, by how much? And under what circumstances? Although this
thesis primarily deals with optimization of fractionation schemes, we are also interested
to know whether spatial adaptation results in further improvement besides that due to
simply changing the fractionation scheme. We seek to identify the types of scenarios in
which adaptivity based on feedback information will be particularly fruitful.
Conventional radiation treatment plans mostly ignore the dynamic nature of the
inherent biological processes in a patient. Over the last 50 years, our understanding
of the biological effects of radiation has improved. With better models and imaging
technologies such as magnetic resonance imaging (MRI) and positron emission tomog-
raphy (PET), biologically-based treatment planning, aiming at optimal dose delivery
over time, has tremendous potential. Yet, the complexities of how radiation affects
the underlying biological processes make it difficult to determine how, if at all, treat-
ment planning should be changed. We seek to understand the relationship between
biological modeling assumptions and the resulting optimal fractionation schedules. We
investigate the circumstances under which these optimal schedules result in significant
improvement over current treatments. We hope that eventually through future research
the best possible individualized treatment can be administered to the patient, taking
into account both geometric and biological uncertainties.
We can dynamically optimize treatment in multiple ways. One way is to make use
of feedback information obtained from computed tomography (CT) or cone beam com-
puted tomography (CBCT) images throughout the course of treatment. If treatment
plans can be optimized and quality assured fast enough, we can adapt treatment im-
mediately before delivery, which is known as online ART; otherwise, we can use oﬄine
16
ART, in which past CT images are used to adapt future treatment. Ideally, we would
like to adapt in real time as geometrical information about the patient anatomy is ob-
tained during the course of treatment. It is also possible to use functional imaging to
observe biological information, e.g., on metabolism, and adapt treatment. If existing
technology cannot be used to observe such biological information, models can still be
used to dynamically adjust a treatment. In the first part of this thesis, we provide
methods to adapt immediately before the delivery of a fraction by using geometrical
information about the patient anatomy. In the second part, we use models of cell dy-
namics to obtain insights about the optimal way to fractionate treatments. In this
thesis, we use dynamic programming as the primary solution method.
1.2 Outline and main contributions
In this section, we provide an overview of the topics covered in this thesis. We briefly
discuss the high level insights of each chapter and the way we approached the problem.
In doing so, we also briefly discuss the main contributions. A more detailed list of
contributions is given in the chapters themselves.
In Chapter 2, we provide an analysis of the adaptive fractionation problem intro-
duced in [48]. A tumor and one primary organ-at-risk (OAR) is considered. The main
idea is to use a large dose to the tumor when observing a favorable patient anatomy and
a small dose when observing an unfavorable anatomy. Given that a fixed prescribed
dose is delivered by the end of treatment, this approach results in a decrease in the
total OAR dose over the course of treatment. We develop and evaluate various solution
methods, both exact and heuristic. We frame the problem in a dynamic programming
framework and derive the structure of an optimal policy. We develop various heuristic
approaches based on the structure of the optimal one. The cost of one of the heuristics
converges to the optimal cost as we increase the number of days of treatment. The
algorithm in [48] is shown to perform very well compared to the optimal even though it
is an approximate DP approach. Though a dynamic programming approach has been
17
used for adaptive fractionation in the past [13], it was in the context of the biological
effective dose (BED) model.
In Chapter 3, we investigate the benefit of adaptive fractionation methods for
prostate cancer patients. We used three patient datasets, each consisting of daily CT
images. We find that adaptive fractionation is beneficial when using the BED model but
not so much when using the physical dose model. We develop an approach to update
the probability distribution of the anatomy favorability over the course of treatment.
Such an approach is found to be useful when historical data from other patients is
not characteristic of the patient-specific anatomy variations from day to day. We also
suggest adaptation by selection of treatment plan from a plan library. The primary
advantage of the plan library is that the quality assurance (QA) procedure is avoided
after the initial plan generation phase. We study a proof-of-principle example in which
the library consists of two plans with different margins around the tumor. We find that
there is significant benefit from adaptive plan selection compared to a conventional
approach. While we mainly decoupled the problems of adaptive fractionation and plan
selection in our work, there were large gains from combining the two approaches.
In Chapter 4, we analyze the effect of accelerated repopulation on optimal fractiona-
tion schemes based on extensions of the BED model. There are multiple ways to model
accelerated repopulation. One approach is to increase the tumor proliferation rate with
already delivered dose or BED. Alternatively, accelerated repopulation can be modeled
implicitly by assuming a proliferation rate that is dependent on the number of tumor
cells. Due to radiation treatment, fewer cells remain towards the end of treatment,
thus resulting in faster tumor growth. We develop a solution approach based on dy-
namic programming to solve the optimal fractionation problem with repopulation for
general tumor growth characteristics. The optimization problem consists of minimizing
the expected number of tumor cells under a constraint on the BED in the OAR. We
prove that the optimal dose fractions are increasing over time. We find that faster
tumor growth suggests shorter overall treatment duration. In addition, the presence of
accelerated repopulation suggests larger dose fractions later in the treatment to com-
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pensate for the increased tumor proliferation. We characterize the special structure of
the problem for the case of exponential and Gompertz tumor growth. More research is
needed to determine tumor repopulation characteristics from clinical outcome data for
specific disease sites.
In Chapter 5, we model the repair effect in addition to tumor repopulation and
generalize the methods in the previous chapter to the case of a continuous dose rate
treatment. We write the dynamics governing the number of tumor cells at any instant
of time as an ordinary differential equation. We show that the proposed continuous-
time model is consistent with the discrete-time one in the previous chapter. Yet, the
work in this chapter is not completely developed and a similar setup is found in [87].
However, we hope that the derivations shed new perspective and provide a basis for
future work.
The final chapter summarizes the thesis and provides directions for future research.
1.3 Background
According to the American Cancer Society, at least 50% of cancer patients undergo
radiation therapy over the course of treatment. Radiation therapy plays an important
role in curing early stage cancer, stopping cancer from spreading to other areas, and
treating symptoms of advanced cancer. For many patients, external beam radiation
therapy is one of the best options for cancer treatment. Another form of radiation
therapy is brachytherapy, in which seeds continuously emitting radiation are placed
inside a patient’s body. In this thesis, we primarily focus on external beam radiation
therapy; thus in this section we will limit our discussion to this form of therapy.
1.3.1 Delivery of radiation treatment
Once a patient is diagnosed with cancer, a simulation 3D CT image of the anatomy is
taken prior to therapy. This CT is the basis for diagnosis and treatment planning. A
19
physician or resident under the supervision of a physician contours the revelant tumor
volume and OARs, and specifies the set of constraints that need to be met in the
treatment plan (e.g., tumor prescribed dose). The primary target for radiation is an
expanded tumor volume. The visible tumor volume on the CT that is cancerous is
known as the gross tumor volume (GTV). To account for uncertainty in microscopic
spread not visible in the CT image, an expanded GTV, known as the clinical target
volume (CTV), is delineated. This is the primary volume that physicians want to
treat. Finally, to account for uncertainty in setup and organ motion from day to day,
a margin is added around the CTV, resulting in the planning target volume (PTV).
For example, for prostate cancer, it is reasonable to include a 5 mm margin uniformly
around the CTV. In the treatment planning phase, the PTV is prescribed a uniform
dose (anywhere between 40 Gy and 80 Gy). There are generally constraints such as a
limit on the maximum or mean dose on critical structures.
The treatment procedure is broken up into many sessions or fractions (where a pa-
tient undergoes at most one session per day). A typical treatment, for example, is 5
sessions per week for 7 weeks. One of the reasons for the above margin expansions of
the tumor volume is due to uncertainty in organ motion. Interfraction motion uncer-
tainty happens between fractions; for example, motion where a patient is setup in a
different position than in the previous session. This causes the target to have a dis-
placement. Intrafraction motion occurs during treatment sessions. An example could
be the breathing of the patient (inhaling and exhaling) which causes the target to move
even as the treatment is ongoing.
Different types of beam modalities can be used for external beam radiation treat-
ment. The two most common ones are photon beams and proton beams. Proton
treatments are preferable to photon treatments due to the nature of the dose as a
function of depth. Once the proton beam penetrates the skin, the dosage increases
exponentially as a function of the depth until it falls sharply down to zero. This allows
for more accurate dosage to the tumor cells but at the same time, is vulnerable to caus-
ing critical errors when uncertainty is present. For a photon beam, however, when the
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beam penetrates the skin, the dosage increases rapidly until it peaks. After peaking,
there is an exponential decrease in dose as a function of the depth. Although photons
are not able to focus the dose as well as protons, they are more robust to uncertainties
such as patient setup errors and organ motion.
After the imaging and contouring phases, the distribution of the radiation dose
on the patient anatomy is optimized. External beams of radiation can be delivered
in multiple ways. For photon beams, developments over the last few decades have
enabled modulation of the intensity of incoming beams as opposed to uniform intensity
using 3D conformal therapy. This modality is known as intensity-modulated radiation
therapy (IMRT). One popular way to deliver IMRT is to use a dynamic multi-leaf
collimator (MLC). The MLC leaves can move dynamically with time and block the
incoming radiation to create intensity modulation of the beam. In this way, instead of
a uniform dose of radiation, a modulated fluence profile is delivered from each beam
angle. Generally, a two step procedure is used in this case. First, the fluence maps of
the beams are optimized. Next, the fluence map is approximately sequenced into MLC
leaf movements. Other approaches such as direct aperture optimization avoid these two
steps altogether and directly optimize the MLC leaves. Intensity modulation can also
be delivered for proton beams, except that an MLC is not used. One way to deliver
the appropriate intensities would be to use beam scanning. This type of treatment is
known as intensity-modulated proton therapy (IMPT). The advantage of this modality
is that the optimized fluence map can be directly mapped with beam scanning and does
not have to be sequenced into MLC leaf trajectories.
1.3.2 Treatment plan optimization
In this subsection, we discuss optimization of the fluence intensity map in the treatment
plan. We omit discussion of MLC leaf sequencing; for references on possible approaches,
see [35, 75].
The basic problem is to optimize beam intensities (or bixel weights) delivered from
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various beams (generally coplanar) around the patient to capture the best tradeoff
between delivering a high dose to the tumor and minimizing the dose to the healthy
tissue. We let x ∈ Rn be the vector of bixel weights. For IMRT, the number of
bixels, n, can range from 1,000 to 100,000. In order to determine the dose delivered
to individual points on the patient (referred to as voxels), a dose deposition matrix
D : Rn → Rm is calculated (generally using Monte Carlo simulations). This deposition
matrix D describes a linear mapping from the vector of bixels x to a vector of doses
delivered to the corresponding patient voxels. The number of patient voxels m ranges
anywhere from 100,000 to 1,000,000 (all the points on a 3D scan of the patient) for a
full-scale problem. There are a number of ways to formulate the problem, including
linear/quadratic and other nonlinear formulations (see [69] for various approaches).
Regardless of the exact details of the formulation, the basic idea is to tradeoff between
dose to the tumor and healthy tissue. Usually, there are constraints on the minimum
tumor dose and maximum or mean dose to healthy OARs.
There are many metrics used to quantify the quality of treatment plan such as mean
or maximum dose to relevant organs of interest. But, often the dose-volume histogram
(DVH) is used to graphically assess the quality of a treatment plan. The DVH curve
for a volume plots the dose versus the percentage of the volume that receives at least
that much dose. In this way, DVH curves are generated for all of the organs of interest
and used for assessment.
1.3.3 Biological effective dose (BED) model
It is known that the effect of the same dose on different types of cancer varies. For
example, prostate cancers are known to be very sensitive to radiation [51] while head
and neck cancers are less so [74]. A common way to quantify this effect is to use the
biological effective dose (BED) model. The BED is defined as
BED = d
(
1 +
d
[α/β]
,
)
(1.1)
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where d is the physical dose and the α-β ratio denoted [α/β] is a tissue specific param-
eter. Essentially, the α and β refer, respectively, to a linear and quadratic dose effect
on tissue. For example, when the linear effect only matters, i.e., if β = 0, the BED
equals the physical dose. We will make use of this model in Chapter 3 when adaptively
varying the fraction size for prostate cancer. For a more detailed derivation of the BED
from linear and quadratic dose effects, refer to Section 4.3 in Chapter 4.
1.4 Literature review
The first part of the thesis (Chapters 2 and 3) fits in the general area of ART. The
second part (Chapters 4 and 5) deals with biological-based treatment planning. In this
section, we begin by surveying the literature in these two broad categories. Then, we
review literature that is more closely related to the work in this thesis. There is a vast
amount of literature in each of these subsections. We do not by any means attempt to
provide a comprehensive review, but rather strive to survey existing work particularly
as they relate to this thesis.
1.4.1 Adaptive radiation therapy
In its broadest context, adaptive radiation therapy (ART) is a radiation treatment
process that uses feedback information to modify and improve treatment plans [41,96].
Feedback information could include patient anatomy information such as positions of
tumor and organ-at-risk (OAR), and can be obtained from imaging modalities such as
cone-beam computed tomography (CBCT), ultrasound imaging, or portal imaging [63].
Detailed coverage of ART can be found in books such as [47].
We can correct for inter-fractional variations in patient anatomy by adapting a
treatment plan either oﬄine or online. An oﬄine adaptation uses imaging information
available after the delivery of a fraction to modify the treatment plan for the next frac-
tion. On the other hand, an online adaptation uses information acquired immediately
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before the delivery of a fraction for a quick modification of the treatment plan for that
fraction. The advantage of online ART is the availability of more data (inclusion of
patient anatomy for the current fraction). However, due to patient wait time and treat-
ment duration limitations, online ART requires (i) fast re-optimization of the treatment
plan, and (ii) re-planning across a small number of degrees of freedom. Conversely, in
oﬄine ART, a re-optimized treatment plan can be determined on a slower time-scale.
Due to the immediate possibility of lower cumulative dose to healthy organs through
treatment plan re-optimization between fractions, oﬄine ART has received much atten-
tion in the research community. One of the early approaches used information about
tumor variations (both systematic and random) during the first few fractions to deter-
mine a customized treatment plan for the remaining fractions [96,97]. The customized
treatment plan generally has a smaller planning target volume (PTV) suited to the
particular patient. Such adaptation is shown to improve treatment efficacy and to al-
low for dose escalation to the tumor [26, 95]. Another approach focused on using a
smaller PTV initially and re-optimizing treatment plans between fractions to compen-
sate for the accumulated dose errors [16, 18, 66, 84, 85]. We do note that the practical
applicability of this method relies on the ability to accurately determine the delivered
dose at each voxel. However, determining the delivered dose accurately requires reliable
deformable registration algorithms, which is still a major research topic.
In online ART, the focus has been on making adjustments to the existing treatment
plan rather than on re-optimizing for an entirely new plan. This is primarily because
the time between the acquisition of patient anatomy information and the delivery of a
plan is on the order of minutes rather than hours. In this case, a full re-optimization
and complete quality assurance of the treatment plan may not be possible. Several
online ART approaches have been developed that make quick modifications to either the
fluence map or multi-leaf collimator (MLC) leaves to match the planned dose [14,53,93].
Whereas these methods involve spatially varying the dose distribution, other methods,
including the work in this thesis, consider temporally varying the fraction size from day
to day [13, 48].
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1.4.2 Biological based treatment planning
One can incorporate biological information into the treatment process by using appro-
priate models in the treatment planning optimization problem. While such models have
uncertainties, they can provide insights on how to potentially improve treatment. In
the future, biological imaging technologies may allow customized delivery to the patient
based on biological processes observed during the course of treatment. Below, we briefly
review some literature in biological based treatment planning.
We can incorporate biological aspects into treatment planning by using models of
tumor and normal tissue response such as tumor control probability (TCP) and normal
tissue complication probability (NTCP). There are many ways to model these probabil-
ities; a short list of references is [33,49,86,99]. Other biologically based models include
the linear-quadratic (LQ) cell survival model [20], the BED model [20], complication-
free tumor control probability [33], and the equivalent uniform dose (EUD) model [56].
Several studies have investigated the use of biological based models for optimizing a
treatment plan [34, 71, 82]. However, due to lack of confidence in the parameters of
these models, such biological-based treatment plans are not universally used in the
clinic. Some studies have cautioned on the use of TCP and NTCP models in treatment
planning due to parameter uncertainty [42, 55].
Using biological information obtained from imaging, it is also possible to adapt treat-
ment. With technological advances such as functional and molecular imaging, there is
potential to track previously unobservable biological processes such as metabolic activ-
ity [68], tumor hypoxia [11], and tumor proliferation rates [3]. One approach is “dose
painting,” where escalated dose is delivered to regions of the tumor exhibiting a different
biological property such as increased radio-resistance. Many dose painting studies have
been conducted using various imaging modalities such as dynamic contrast-enhanced
MRI [80], 18F-fluorocholine PET [62], and 11C-choline PET [10]. Other sophisticated
approaches such as dynamically changing the beam intensities from day-to-day based
on the patient’s biological condition have also been studied [23, 38, 40].
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1.4.3 Overview of literature in relation to thesis
We primarily use the dynamic programming (DP) approach in this thesis. The DP
approach is useful for sequential decision making problems, especially when there is a
need for balancing the immediate and future costs associated with making a decision at
any particular stage [4,64]. For oﬄine ART, the DP approach can be used to compensate
for past accumulated errors in dose to the tumor [18, 19, 70]. For online ART, an
approach for adaptive fractionation based on biological models and imaging also makes
use of DP [13,39]. A spatiotemporal DP approach that adapts to the patient’s biological
condition has also been recently been studied [40]. There is a significant amount of
literature, especially from the mathematical biology community, on optimal control
theory and DP for cancer treatment. Many of these works [44,60,100] have looked into
optimization of chemotherapy. For radiation therapy fractionation without the use of
imaging information, many studies [1, 28, 87] have used the DP approach and control
theory based on deterministic biological models. The work in Chapter 4 follows this
line of thought but is motivated by accelerated tumor repopulation.
Chapters 2 and 3 of this thesis deal with adaptive fractionation, which is a special
case of online ART. Adaptive fractionation assuming a physical dose model was intro-
duced in [48]. In Chapter 2, we solve the adaptive fractionation problem using a DP
approach; the results are also published in [65]. For the BED model, a DP approach
was used to solve the adaptive fractionation problem in [13]. In a similar spirit, the
work in [39] selects a dose based on the patient’s observed biological condition. In
Chapter 3, a method that can adapt the belief about the patient’s future condition
into the DP approach is also introduced. Even with several works that have described
possible adaptive fractionation approaches, such methods have not been substantiated
by results from patient datasets. In Chapter 3, prostate patient data is used to show
that adaptive fractionation (and also treatment plan selection from a plan library) can
be beneficial.
Chapters 4 and 5 deal with the effect of tumor repopulation on optimal fractiona-
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tion schemes. There is a large amount of literature on optimal fractionation; we mainly
discuss papers that relate to our work. Previous works have considered the case of
exponential tumor growth with a constant rate of repopulation [2,32,88]. Optimal frac-
tionation schedules for other tumor growth models, e.g., Gompertz and logistic, have
also been considered although mostly in the context of constant daily doses [50, 79].
Using the BED model, a recent paper [52] has mathematically analyzed the fraction-
ation problem for the case of no repopulation. An extension of this result to the case
where an inhomogeneous OAR dose is delivered has also been investigated [78]. The
work in Chapter 4 extends the mathematical framework in [52] by incorporating tu-
mor repopulation. There has been prior work [1, 76, 77, 94, 98] on the optimization of
non-uniform fractionation schedules, even analyzing the effect of tumor repopulation
as done in this thesis. However, they either have not used the BED model or have
primarily considered other factors such as tumor re-oxygenation. Perhaps the closest
work is [87], which considers both faster tumor proliferation and re-oxygenation during
the course of treatment. However, while a dose intensification strategy is also suggested
in [87], the rationale for dose escalation is different: it is concluded that due to the in-
crease in tumor sensitivity from re-oxygenation, larger fraction sizes are more effective
at the end of treatment. Our work, on the other hand, suggests dose escalation due to
accelerated tumor repopulation during the course of treatment.
In Chapter 4, we are primarily motivated by accelerated repopulation, which is an
important cause of treatment failure in radiation therapy, especially for head and neck
tumors [91, 92]. In addition to modeling tumor growth, we use the standard linear-
quadratic (LQ) model [15] to describe the effects of radiation dose on the survival
fraction of cells. Since our primary interest is in the effect of tumor repopulation, we
do not consider other biological aspects such as re-oxygenation, re-distribution, and
sublethal damage due to incomplete repair. However, it has been shown that such
effects can also result in non-uniform optimal fractionation schemes [5, 87, 98]. Our
main result is that accelerated repopulation suggests larger dose fractions later in the
treatment to compensate for increased tumor proliferation. The results are consistent
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with medical-oriented studies for prostate and cervical cancers [29, 81].
The notion of dose intensification during the course of treatment has now been
suggested by many studies, including our work. The Norton-Simon hypothesis [57, 58]
suggests increasing the dose intensity over the course of chemotherapy due to a Gom-
pertzian tumor growth assumption. Due to the increased sensitivity of the tumor to
radiation from re-oxygenation, such a dose intensification strategy has also been sug-
gested by several studies [1,28,87]. It has been noted in [61] that increased oxygenation
and proliferation at the end of treatment could be one reason for the effectiveness of
concomitant boost therapy, where increased radiation is delivered at the very end of
treatment. Medical-oriented studies [29,81] also suggest larger fraction sizes to compen-
sate for accelerated repopulation. This is consistent with our mathematical framework
incorporating accelerated tumor repopulation. Further clinical studies that substantiate
the dose intensification strategy would be useful.
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Chapter 2
A dynamic programming approach
to adaptive fractionation
2.1 Introduction
In this chapter, we consider delivering a different dose to the tumor each day depending
on the observed patient anatomy. We study various solution methods for this adaptive
fractionation problem. The two messages of this chapter are: (i) dynamic program-
ming (DP) is a useful framework for adaptive radiation therapy, particularly adaptive
fractionation, because it allows us to assess how close to optimal different methods are,
and (ii) the proposed heuristic methods are near-optimal, and therefore, can be used
to evaluate the best possible benefit of using an adaptive fraction size.
We now briefly motivate the adaptive fractionation problem introduced in [48]. We
focus on a model of the variations of the tumor and one primary OAR, which is usually
the limiting factor in escalating the dose to the tumor. Using an adaptive fraction
size can allow us to take advantage of a “favorable” patient anatomy by increasing the
fraction size. Similarly, we can decrease the fraction size for an “unfavorable” anatomy.
One simple way to think about this problem is to consider variations of the distance
between the tumor and the OAR from day to day (see Figure 2-1). If the distance is
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Figure 2-1: Adaptive fractionation capitalizes on tumor-OAR variations. Nominal dose
corresponds to leaving the fraction size unchanged, while scaled dose corresponds to a
changed fraction size. When we have a favorable anatomy (i.e., the tumor and OAR
are far apart) as in the left panel, we can use a larger fraction size. Similarly, for an
unfavorable anatomy (i.e., the tumor and OAR are close together) as in the right panel,
we can use a smaller fraction size. Our model is more general than this 1-dimensional
example and can be used for 3-dimensional realistic settings as well.
large, we can escalate the dose to the tumor (since the OAR dose per unit tumor dose is
small) and vice versa, if the distance is small. Given that a fixed prescribed dose must
be delivered to the tumor, adaptive fractionation results in a lower cumulative dose
to the OAR over the course of the treatment. We emphasize that our model is more
general than this 1-dimensional distance setting and can be applied to 3-dimensional
realistic settings as well.
The purpose of this study is to develop and evaluate solution methods for the adap-
tive fractionation problem. We use the dynamic programming (DP) algorithm to solve
the problem exactly and to assess how close to optimal various heuristic methods are.
The dynamic programming approach has been used before for adaptive fractionation
in [13], but this was in the context of the BED model. We focus on the fractionation
problem using a physical dose model, which was introduced in [48]. The results of
our study indicate that heuristic methods, both the ones proposed in this chapter and
in [48], are near-optimal under most conditions. The consequence is that these methods
can be used to evaluate in a simple manner the best possible benefit of using an adap-
tive fraction size. Furthermore, simple heuristics as proposed in this chapter provide a
quick way to measure the gain that results from adaptively varying the fraction size.
We first discuss the main contributions of this chapter in Section 2.2. In the next
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section, we discuss the model and formulate the adaptive fractionation problem. Sec-
tions 2.4 and 2.5 describe the dynamic programming (DP) approach and its theoretical
properties, and Section 2.6 describes two heuristics. In Section 2.7, the algorithm in [48]
is derived and shown to be a variant of the open-loop feedback control approximate DP
approach. Results from numerical simulations are evaluated in Section 2.8. Some fur-
ther theoretical properties of one of the heuristics are described in Section 2.9. Finally,
Section 2.10 includes discussions about realistic implementations, model assumptions,
and future directions.
2.2 Contributions
The idea of adaptive fractionation is not new; it was already introduced and an al-
gorithm was developed in [48]. Our contributions include further developing solution
methods and analyzing them on a theoretical level. In particular, we:
1. use the DP algorithm to establish a benchmark and to solve the problem exactly.
Under this problem setting, this gives us a lower bound which no other algorithm
can improve upon. We are able to show numerically that many of the heuristic
algorithms, including the one in [48], perform close to optimal for most assumed
probability distributions of the patient anatomy. However, when there is a high
probability of large tumor-OAR distances, we see differences as large as 10%
between an optimal policy and the algorithm in [48].
2. prove properties of an optimal policy and find that for most realistic cases, an
optimal policy has a special threshold form.
3. develop two intuitive, numerically near-optimal heuristic policies, which could
be used for more complex, high-dimensional problems. Furthermore, one of the
heuristics requires only a simple statistic (e.g., the median) of the motion proba-
bility distribution, making it a reasonable method for realistic settings.
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4. establish clearly the connection between this work and the one in [48] by rederiving
the algorithm in [48] as a variant of the open-loop feedback control approximate
DP approach (see [4] for a description of such an approach).
5. demonstrate through numerical simulations that we can expect a significant de-
crease in dose to the OAR when: (i) we have a high probability of large tumor-
OAR distances, (ii) we use many fractions (as in a hyper-fractionated setting),
and (iii) we allow large daily fraction size deviations.
6. prove that one of the proposed heuristics is asymptotically optimal as the number
of treatments N is large. The rate of convergence is O
(√
logN√
N
)
.
2.3 Model and formulation
We now describe the details of the model and formulate the adaptive fractionation
problem. Let N be the number of fractions and P be the total prescribed dose to
the tumor. The patient anatomy in the kth day is represented by a variable denoted
by sk, which is sampled, independent of everything else, from a known probability
distribution p(·) estimated from historical data. We assume that the patient anatomy
sk is observed just before the delivery of the kth fraction and can be obtained, for
example, from imaging modalities such as CBCT. We could also use this formulation
for intra-fractional variations, where sk would change during a fraction; in this case,
it would be more appropriate to assume that patient anatomy instances are correlated
rather than independent from one another. In general, the distribution p(·) can be
either continuous or discrete but for simplicity, we assume a continuous distribution and
denote by S the set of possible anatomy instances. We define rk to be the remaining
prescribed dose left to deliver to the tumor in the kth and future fractions. We must
determine the fraction size uk in the kth fraction based on the remaining dose rk and
patient anatomy sk. Here, rk and sk together represent the state of the system because
they are the only relevant pieces of information needed to determine the fraction size
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uk. It can be seen that the dynamics of the system are described by the equations
rk+1 = rk − uk, sk ∼ p(·), for k = 1, 2, . . . , N , with r1 initialized to the prescribed dose
P .
Given a patient anatomy sk, the dose delivered to the OAR in the kth fraction
can be written as ukh(sk), where h(sk) is the OAR dose per unit Gy dose delivered to
the tumor. For the 1-dimensional setting in Figure 2-1, the function h(sk) describes
the dose falloff, as a function of the location of the OAR. We could use other choices
for h(sk); what we need is a function that describes how favorable a particular patient
anatomy sk is. If current technology allows for a quick way to supply information about
the favorability of a patient anatomy before the delivery of a fraction, this information
can be captured in the h(sk) function. The main assumption here that a linear increase
in the dose to the tumor results in a linear increase in the dose to the OAR, which
is reasonable and is used in practice. For notational convenience, we also define the
cumulative distribution function (CDF) for h(sk) as
F h(z) =
∫
{s : h(s)≤z}
p(s) ds. (2.1)
In the model description, we have included the patient anatomy sk as a state variable.
However, this could result in a very high-dimensional state space if the entire 3D or 4D
anatomy information is included. In the following remark, we suggest an alternative
but equivalent state space description for this problem.
Remark 1. We could use h(sk) as the state instead of the entire anatomical information
given by sk. This would reduce the state space to a 2D quantity (rk, h(sk)). In this case,
instead of p(·), we would use the relevant probability distribution ph(·) associated with
the CDF F h(·) defined in (2.1).
The optimization problem of interest is to minimize the expected total dose to the
OAR subject to constraints that ensure that: (i) the prescribed dose to the tumor is
met with certainty, and (ii) the fraction size for each day is within a lower bound, u,
and an upper bound, u. Although optimizing non-linear TCP/NTCP functions might
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be a better choice here, it is simpler to use total dose, which is a reasonable surrogate
for most situations. For convenience in analysis, we also incorporate constraint (i) into
the objective cost function by adding a terminal cost g(rN+1), which assigns an infinite
penalty when the prescribed dose P is not met. Mathematically, we can formulate the
adaptive fractionation problem as follows:
min
{µk}
E
[
g(rN+1) +
N∑
k=1
µk(rk, sk)h(sk)
]
s.t. u ≤ µk(rk, sk) ≤ u, k = 1, 2, . . . , N, ∀rk, ∀sk
r1 = P,
rk+1 = rk − µk(rk, sk), k = 1, 2, . . . , N,
sk ∼ p(·), k = 1, 2, . . . , N,
(2.2)
where
g(rN+1) =
 0, if rN+1 = 0,∞, otherwise,
and where the expectation E[ · ] is taken with respect to the probability distribution
p(·).
In the above optimization problem, we are searching for an optimal policy µ∗k(rk, sk),
which for any given time k, is a function of the remaining dose rk and the patient
anatomy sk. Here, the solution is not simply a single value of the optimal fraction
size for any particular day but rather, a policy or a strategy that can possibly choose
different fraction sizes based on state information. This is characteristic of closed-loop
control, which uses state (feedback) information to make decisions. Furthermore, a
brute search over all possible functions µ(rk, sk) to solve this problem is not feasible.
Notice that the first term in the objective function g(rN+1) simply ensures that after
N fractions, the prescribed dose to the tumor is met exactly. The second term is the
total dose to the OAR resulting from using the policy µk.
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2.4 A dynamic programming approach
We can solve the problem (2.2) exactly by using the DP algorithm (Bellman’s backward
recursion):
JN+1(rN+1, sN+1) = g(rN+1) =
 0, if rN+1 = 0,∞, otherwise,
Jk(rk, sk) = min
u≤uk≤u
(
ukh(sk) + E [Jk+1(rk − uk, sk+1)]
)
, (2.3)
for k = N,N − 1, . . . , 1, where the expectation is taken with respect to the distribution
p(·) of sk+1:
E [Jk+1(rk − uk, sk+1)] =
∫
S
p(s)Jk+1(rk − uk, s) ds.
For numerical implementation, however, we need to discretize the variables rk and sk
and solve a corresponding discrete problem. All of our subsequent numerical results
refer to this discrete problem.
It is well known that the policy resulting from the above DP algorithm is optimal
for the problem (2.2) — see [4]. Hence, the cost-to-go function Jk(rk, sk) is the resulting
cost from using an optimal policy starting with a given remaining dose rk and patient
anatomy sk in the kth fraction. The basic idea of the DP algorithm is to start from
the last fraction (when the optimal decision µ∗N must be exactly equal to the remaining
dose rN for any possible sN), determine the optimal decision µ
∗
N−1 given this new
information, and proceed backwards in determining the present optimal policy with
information about future optimal policies. We can see that Jk(rk, sk) is computed by
minimizing the sum of the present cost associated with delivering the fraction size uk in
the kth fraction (i.e., ukh(sk)) and the expected future cost resulting from delivering the
fraction size uk given that we use an optimal policy thereafter (i.e., E [Jk+1(rk − uk, s)]).
Essentially, the DP algorithm involves precomputing oﬄine and storing the fraction size
uk, for every possible fraction k and value of the state (rk, sk). Therefore, choosing the
fraction size online right before the delivery of the fraction simply involves a quick table
lookup. A few observations about simplifying the DP algorithm in (2.3) are given in
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the following remark.
Remark 2. As suggested in Remark 1, we can simplify the DP algorithm by reducing
the state space to a 2D quantity (rk, h(sk)). A second simplification involves removing
the uncontrollable state sk (or equivalently, h(sk)) by “averaging it out” and keeping
track only of expected cost-to-go functions. For completeness, the simplified algorithm
is given below.
JN+1(rN+1) = g(rN+1) =
 0, if rN+1 = 0,∞, otherwise,
Jk(rk) = E
[
min
u≤uk≤u
(
ukh(sk) + Jk+1(rk − uk)
)]
, (2.4)
for k = N,N − 1, . . . , 1. For ease of exposition, we still use the original DP algorithm
given in (2.3) for the analysis and discussions in this chapter.
We now summarize interesting theoretical properties of an optimal policy resulting
from the qualitative structure of the cost-to-function. The piecewise linear structure of
the cost-to-go function (see next section for details) results in a special structure of an
optimal policy. Essentially, if it is possible to deliver the treatment with a sequence of
smallest fraction sizes u and largest ones u, an optimal policy does exactly that, i.e.,
the resulting optimal policy has the threshold structure:
µ∗k(rk, sk) =
 u, if h(sk) ≥ Tk(rk),u, if h(sk) < Tk(rk), (2.5)
for k = 1, 2, . . . , N , where the Tk(rk) are pre-computed thresholds (see next section for
details). The optimal policy (2.5) makes sense because unfavorable or large values of
h(sk) result in delivering a small fraction size u and vice versa. The policy is completely
characterized by the thresholds Tk(rk), k = 1, 2, . . . , N , which represent the points at
which it is optimal to deliver u when above it and u when below it. We note that
because the optimal policy has the structure (2.5), we can restrict the search for uk in
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(2.3) to the set {u, u} rather than the entire range of values between them and still
preserve optimality. Furthermore, as we will see in a future section, this structure of an
optimal policy can serve as the basis for simpler heuristics that could perform very close
to the optimal. To get further intuition about the optimal policy, let us consider the
case where the sequence of patient anatomy instances or costs h(sk), k = 1, 2, . . . , N ,
are known ahead of time for the entire treatment. Then, it is clear that the solution
would be to deliver u for the fractions with the smaller costs and u otherwise. Now, we
can view our original problem, where the information about the patient anatomy is only
available before the delivery of the fraction, as one of deciding whether the anatomy of
any particular day will be one of the fractions with the smaller costs. The threshold
Tk(rk) helps us make this determination.
2.5 Theoretical properties of the optimal policy
We provide additional details on the theoretical properties of optimal policies, after
first commenting on a generalization of our previously stated assumptions.
Remark 3. Although we assumed sk to be independent and identically distributed in the
previous section, our methods apply more generally to the case where the sequence of pa-
tient anatomy instances satisfy the Markov property. That is, the patient anatomy sk+1
is only dependent on sk and not on previous anatomies before the kth day. In this case,
the dependencies would be summarized in a new probability distribution pk(sk+1|sk); the
analysis and results in this section would still go through.
To facilitate the discussion, we define
Fk = {rk : (N − k + 1)u ≤ rk ≤ (N − k + 1)u} , (2.6)
Bk(rk) = max(u, rk − (N − k)u),
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and
Bk(rk) = min(u, rk − (N − k)u)).
The set Fk represents the feasible set of remaining dose values in the kth fraction. We
can verify this by noting that because the prescribed dose to the tumor must be met
exactly, the remaining dose rk must be between the smallest and the largest possible
fraction size deliverable to the tumor for the remaining fractions (i.e., (N −k+1)u and
(N − k + 1)u). As we will see below in Lemma 2.5.1, we can rewrite a simplified DP
algorithm in which Bk(rk) and Bk(rk) can be interpreted as the minimum and maximum
allowable dose in the kth fraction, respectively. We assume that the minimum of a
function over an empty set is equal to infinity.
Lemma 2.5.1. The DP algorithm given in (2.3) can be rewritten as follows
Jk(rk, sk) = min
Bk(rk)≤uk≤Bk(rk)
(
ukh(sk) + Jk+1(rk − uk)
)
, (2.7)
with the same terminal condition as before.
Proof. See Appendix 2.11.1.
In the following theorem (see Figure 2-2), we describe the qualitative structure of
the cost-to-go function and characterize the structure of an optimal policy.
Theorem 2.5.2. The cost-to-go function Jk(rk, sk), for k = 1, 2, . . . , N , is continuous,
non-decreasing, convex, and piecewise linear in rk for rk ∈ Fk, with breakpoints at
(N − k+1− i)u+ iu, for i = 0, 1, . . . , N − k+1. Furthermore, there exists an optimal
policy, for k = 1, 2, . . . , N , with the form:
µk(rk, sk) =

u, if rk ≥ u+ Ak(sk)
rk − Ak(sk), if u+ Ak(sk) ≤ rk < u+ Ak(sk)
u, if rk < u+ Ak(sk),
(2.8)
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rk
Jk(rk, sk)
...
0 1 2 N – k+1
Figure 2-2: Special structure of the cost-to-go function Jk(rk, sk). For simplicity, we
use u = 0 and u = 1 for the plot and see that Jk has N − k + 1 line segments and
breakpoints at all integer points in the range [0, N − k + 1].
where Ak(sk) = argmin
y∈Fk+1
[−yh(sk) + Jk+1(y)].
Proof. See Appendix 2.11.2.
The interpretation of the above optimal policy structure is that for a fixed patient
anatomy sk, provided that the dose stays within the lower bound u and upper bound u,
an optimal policy is to deliver a dose which linearly increases with the remaining dose
rk. If we fix the remaining dose rk, we find an optimal policy stated in the corollary
below.
Corollary 2.5.3. There exists an optimal policy, for k = 1, 2, . . . , N , which has the
form:
µk(rk, sk) =

Bk(rk), if h(sk) ≥ Ck(rk)
rk − ((N − k − i∗)u+ i∗u), if Dk(rk) ≤ h(sk) < Ck(rk)
Bk(rk), if h(sk) < Dk(rk),
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where i∗ is an integer between 0 and N − k such that (rk − ((N − k − i∗)u + i∗u)) ∈
[Bk(rk), Bk(rk)].
Proof. See Appendix 2.11.3.
For a fixed remaining dose rk, the above corollary states that an optimal policy will
take exactly one of three values: the minimum dose deliverable when the cost of the
patient anatomy h(sk) is above a point Ck(rk), rk− ((N −k− i∗)u+ i∗u) when the cost
h(sk) is between the points Dk(rk) and Ck(rk), and the maximum dose deliverable when
the cost h(sk) is below Dk(rk). By running the discretized DP algorithm on Matlab
using reasonable parameters, we plot the optimal policy decision region for the 15th day
(midway through treatment) in Figure 2-3 and see that it has the properties described
by the above two results.
An additional special consequence of the above theorem is that when it is possible to
deliver the treatment with a sequence of smallest and largest fraction sizes (i.e., when
rk is a nonnegative integer combination of u and u), an optimal policy does exactly
that. Moreover, an optimal policy has a threshold form and is essentially unique when
the probability distribution p(·) is continuous. This is stated mathematically in the
following corollary.
Corollary 2.5.4. If there exists an integer i between 0 and N such that the initial
remaining dose (or the prescribed dose) can be written as r1 = (N − i)u+ iu, then there
exists an optimal policy of the threshold form:
µ∗k(rk, sk) =
 u if h(sk) ≥ Tk(rk),u if h(sk) < Tk(rk), (2.9)
for k = 1, 2, . . . , N . Furthermore, this is the unique optimal policy (except possibly on
a zero probability set) if the probability distribution p(·) is continuous.
Proof. We proceed by induction. Let k = 1 and assume, for the base case, that there
exists an integer i1 between 0 and N such that the initial remaining dose (or the
prescribed dose) can be written as r1 = (N − i1)u+ i1u. We consider three cases:
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Figure 2-3: Decision region of an optimal policy. We use the following input parameters
to the DP algorithm: N = 30, P = 60 Gy, u = 1.6 Gy, u = 2.4 Gy, p(sk) ∼ U [0, 1], and
h(sk) = 1− sk. We see that the plotted optimal policy agrees with Corollary 2.5.3, and
for a fixed remaining dose, takes on exactly three values. We also observe that for a
fixed tumor-OAR distance, the optimal policy delivers a dose which linearly increases
with the remaining dose (truncated at the limits so that the fraction size stays within
the interval [u, u]), which is in agreement with Theorem 2.5.2. The white streaks in the
plot are probably due to discretization errors.
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1. When i1 = 0, i.e. r1 = Nu, the only possible solution is u1 = u2 = . . . = uN = u,
in which case we are done.
2. Similarly, when i1 = N , u1 = u2 = . . . = uN = u is the only solution.
3. We consider the more interesting case when i1 is an integer between 1 and N − 1.
First, we notice that for any choice of u1 between u and u, r2 = r1 − u1 remains
feasible, and hence, the cost-to-go function J2(r1 − u1, s) is finite for all anatomy
instances s. Second, since r1 = (N − i1)u + i1u, from Theorem 2.5.2, we have
that J2(r1 − u1, s) is linear in u1 for all values in between u and u. Since taking
an expectation preserves linearity, the function E [J2(r1 − u1, s2)] is also linear in
u1. Now, in the DP equation
J1(r1, s1) = min
u≤u1≤u
(
u1h(s1) + E [J2(r1 − u1, s2)]
)
, (2.10)
we are minimizing a linear function because adding a linear function u1h(s1)
preserves linearity. So, for any feasible r1, we can write
E [J2(r1 − u1, s2)] = a(r1)u1 + b(r1),
where a(r1) and b(r1) represent the slope and intercept, respectively. Let T1(r1) =
−a(r1). Then, since we are minimizing a linear function over an interval in (2.10),
µ∗1(r1, s1) has the desired threshold form:
µ∗1(r1, s1) =
 u, if h(s1) ≥ T1(r1),u, if h(s1) < T1(r1).
Now, it is clear that from the above form for µ∗1(r1, s1), there exists an integer i2
between 0 and N − 1 such that the remaining dose in the next fraction can be
written as r2 = (N − 1− i2)u+ i2u. We can complete the induction by assuming
the appropriate form for rk in the induction hypothesis and following the same
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line of argument as above.
Notice that if h(sk) = Tk(rk), any choice of µk between u and u will be optimal. In
fact, this is exactly the set of all optimal decisions. However, under the assumption
that p(·) is continuous, the event h(sk) = Tk(rk) happens with zero probability, and
therefore, we need not specify the value of µk for this case. It follows that the policy
(2.9) is essentially unique when p(·) is continuous.
There is also a similar result to Corollary 2.5.4, in which the threshold condition is
written in terms of rk (as opposed to h(sk)); it can be derived using similar arguments
as in the above results. The assumption in Corollary 2.5.4 that the initial remaining
dose can be written as r1 = (N − i)u+ iu simply requires that it be possible to deliver
the treatment with a sequence of smallest fraction sizes u and largest ones u. Otherwise,
it would not be possible for the cumulative sum of the fraction sizes to be equal to the
prescribed dose when restricting to only the smallest or the largest fraction size. In
that respect, the assumption here is reasonable and is generally satisfied in a realistic
setting or at least satisfiable with a slight modification of the lower bound u and upper
bound u. For the case of continuous p(·), the uniqueness of the policies in Theorem
2.5.2 and Corollary 2.5.3 can be shown in a similar way as in the proof of Corollary
2.5.4.
2.6 Heuristic policies based on optimal policy struc-
ture
Although it is possible to solve the problem exactly using the DP algorithm, we develop
two heuristics that make use of the structure of an optimal policy and approximate the
threshold Tk(rk) in (2.5) by using: (i) the remaining dose rk, which summarizes past
information, and (ii) the distribution p(·), which summarizes information about the
expected patient anatomy in the future. We believe that such heuristics can provide
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simpler and intuitive solutions that can possibly be applied to more complex, high-
dimensional problems, where using the DP algorithm is no longer computationally
feasible.
Without loss of generality we assume 0 ≤ h(sk) ≤ 1, for all sk. For simplicity we
assume that (u+u)/2 = P/N , so that u and u need each to be applied half of the time
over the course of treatment. Our Heuristic 1 uses the following threshold:
Tk(rk) =

0, if rk = (N − k + 1)u,
1, if rk = (N − k + 1)u,
M, otherwise,
where M is the median of h(sk), which by definition satisfies F
h(M) = 1
2
. Such a policy
has a simple interpretation: If the remaining dose rk in the kth fraction is such that
we must deliver the smallest fraction size u for the remaining fractions (in which case
rk = (N − k + 1)u), we set the threshold to 0, ensuring that regardless of the anatomy
sk, we always deliver the smallest fraction size u. And, similarly, if the remaining dose
rk is (N − k+1)u, we set the threshold to 1 and as a result, deliver the largest fraction
size u for the remaining fractions. Otherwise, for the interesting case when rk is between
(N−k)u and (N−k)u, this policy simply delivers the smallest fraction size u when the
cost h(sk) is above its median M (on average, this will happen half of the time) and the
largest fraction size u when below it (on average, this will happen the other half of the
time). Ignoring the possibility that the threshold Tk(rk), for k = 1, 2, . . . , N , can take
extreme values (either 0 or 1), this policy is stationary, in the sense that the thresholds
do not change with the fraction k. This is a simplistic approximation to the true values
of Tk(rk). The nice feature of this policy is that we do not need all of the information
given in the probability distribution p(·); the only information required is the median
M of h(sk). This could be useful in a realistic setting in which we do not actually have
accurate information about the distribution p(·). Here, one could estimate the median
M (perhaps by using statistical information from many patient datasets) and use the
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above heuristic policy.
An even better heuristic policy might use the entire distribution p(·) (as opposed to
just a statistic such as the median or mean) to determine the threshold Tk(rk). Consider
Heuristic 2, which uses a threshold Tk(rk) that satisfies
F h(Tk(rk)) =
ik
N − k + 1 , (2.11)
where ik is the number of largest fraction sizes u left to deliver in the remaining N−k+1
fractions. Given that Tk(rk) is fixed for the remaining N −k+1 fractions, the left hand
side of (2.11) represents the percentage of the remaining fractions for which we expect
to deliver the largest fraction size u. And the right hand side represents the percentage
of the remaining N − k+1 fractions for which we must deliver the largest fraction size
u. In some sense, this threshold represents the best balance between what we expect
to deliver and what we must deliver. For the uniform distribution, i.e. h(sk) ∼ U [0, 1],
the threshold Tk(rk) for Heuristic 2 has a simple closed form expression:
Tk(rk) =
ik
N − k + 1 .
Of course, it may not be possible to write Tk(rk) as a closed form expression but it can
be evaluated by looking at tabulated values of the function F h(·).1
2.7 Algorithm based on a variant of open-loop feed-
back control
In this section, we derive the algorithm in [48] as a variant of the approximate DP
approach known as the open-loop feedback control (see [4] for a description of this
1For the case of a discrete probability distribution with a few possible patient anatomy instances,
a naive implementation of Heuristic 2 can result in the threshold taking a value of 0 even though it is
not necessary to deliver the smallest fraction size u for the remaining fractions. In such cases, in our
numerical experiments, we forced the heuristic to deliver the largest fraction size u when h(sk) = 0,
and this resulted in better performance.
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approach).
Recall from previous sections that, to solve the original optimization problem in
(2.2), we use the DP Algorithm specified by (2.3). The expected cost-to-go function
Jk+1(rk − uk) in (2.4) represents the expected future cost of delivering the control uk
given that we use an optimal policy in the future. We consider a suboptimal approach
which approximates the cost-to-go function Jk+1 by evaluating the cost incurred from
using a heuristic policy in the future instead of an optimal one. Let us consider using a
stationary policy (i.e., one that does not depend on time) which is independent of the
future states, ri for i = k + 1, k + 2, . . . , N . This translates to replacing µi(ri, si) with
µ(s) = µ(sk+1) = µ(sk+2) = . . . = µ(sN) in the optimization problem (2.2). Therefore,
in the kth fraction (when the states rk and sk are known), we would be solving the
following problem:
min
uk, µ
E
[
g(rN+1) + gk(sk, uk) +
N∑
i=k+1
gi(µ(Vi), Vi)
]
subject to u ≤ uk ≤ u,
u ≤ µ(s) ≤ u, ∀s ∈ S,
rk+1 = rk − uk,
ri+1 = ri − µ(Vi), i = k + 1, k + 2, . . . , N,
Vi+1 ∼ p(·), i = k, k + 1, . . . , N,
where we distinguish the random future anatomies by Vi and the observed (known)
anatomy sk. Since we assume Vi are independent and identically distributed, the expec-
tation of the summation in the objective above simplifies to (N−k) identical terms. Now
we can remove the function g(rN+1) by including the constraint B(rk) ≤ uk ≤ B(rk).
Finally, we approximate the dynamics of the system rk+1 = rk − uk, ri+1 = ri − µ(Vi),
and si+1 ∼ p(·) by ensuring the expected delivered dose is equal to the prescription
dose. This is captured by the equation uk + (N − k)E [µ(Vk)] = rk. After these modi-
fications, we obtain the following linear programming (LP) formulation to solve in the
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kth fraction:
min
uk, µ
ukh(sk) + (N − k)E [µ(Vk)h(Vk)]
subject to B(rk) ≤ uk ≤ B(rk),
u ≤ µ(s) ≤ u, ∀s ∈ S,
uk + (N − k)E [µ(Vk)] = rk,
where we take the expectation with respect to the distribution p(·). The LP algorithm
above is the same algorithm as the one in [48]. We have derived this algorithm under
our problem framework and clearly established the relationship between this work and
the one in [48].
2.8 Numerical results
We discuss the results from implementing the adaptive algorithms (both exact and
heuristic) in Matlab. For the problem parameters, we take the number of fractions N
to be 30, the prescribed dose P to be 60 Gy, the smallest fraction size u to be 1.6 Gy,
the largest fraction size u to be 2.4 Gy, the set of patient anatomy instances S to be 10
equally spaced values between 0 and 1 representing the distance between the tumor and
OAR (see Figure 2-1), the distribution p(·) to be a discrete uniform, and the function
h(sk) to be 1 − sk. Essentially, we are allowing for a 20% daily fraction size deviation
from the standard 2 Gy per fraction.
We find that both Heuristic 1 and 2 do well in approximating the optimal threshold,
and as a result, perform numerically close to optimal. In Figure 2-4, for one treatment
simulation (i.e., one realization of the sequence {s1, s2, . . . , sN}), we show the thresh-
olds of the optimal and heuristic policies. When the tumor-OAR distance sk is large
and above the threshold, which indicates a favorable anatomy, the policy delivers the
largest fraction size u, and vice versa. We note that, for this 1-dimensional setting, the
threshold in Figure 2-4 is equal to 1− Tk(rk) because we are plotting the tumor-OAR
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Figure 2-4: Thresholds of optimal and heuristic policies resulting from one treatment
simulation run (i.e., one realization of the patient anatomy sequence {s1, s2, . . . , sN}).
For this 1-dimensional example, the threshold lines plotted represent the point at which
a policy delivers the smallest fraction size u when sk is below it and the largest fraction
size u when above it. These lines plotted are actually 1−Tk(rk) because we are plotting
sk instead of h(sk) = 1 − sk. The ‘x’ markers correspond to the actual realization of
the tumor-OAR distance sk. Heuristic 1 (Heu1) makes a crude approximation to the
optimal threshold while Heuristic 2 (Heu2) follows it closely. Since the ‘x’ markers are
uniformly spread out and rarely take values near the thresholds, the heuristic algorithms
perform well compared to the optimal DP approach.
distance sk on the y-axis rather than h(sk). While Heuristic 2 closely approximates
the optimal threshold, Heuristic 1 makes a crude approximation since it only uses the
median M of h(sk). Since the realized tumor-OAR distances sk (as shown by the ‘x’
markers) are uniformly spread out and rarely take values near the thresholds, we see
that the heuristic algorithms perform well.
In Table 2.1, we see that when using a uniformly distributed motion model, the
adaptive policies result in about a 10% decrease in dose to the OAR compared to that
resulting from standard fractionation. Note that the DP approach represents the opti-
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Table 2.1: Using a uniformly distributed motion model and a 20% daily fraction size
deviation, we find about a 10% decrease in dose to the OAR when using adaptive
policies. The dose to the OAR is averaged over 10,000 treatment runs in order to
report results to two decimal places.
Average Dose to OAR
Standard Fractionation 30.00
DP (Optimal) 27.00
Heuristic 1 27.13
Heuristic 2 27.00
Algorithm in [48] 27.07
mal policy, and hence, provides a baseline for comparison to the other heuristics. The
difference in the dose to the OAR resulting from Heuristic 1 and the DP approach is
very little, which means that using a statistic such as the median M of h(sk) is enough
for achieving significant decrease in dose to the OAR. Such a policy could be advanta-
geous in a realistic setting when it is not possible to have accurate information about
the distribution p(·). As expected, Heuristic 2 performs even better than Heuristic 1
since it uses the entire distribution p(·) in the threshold computation. We can see that
the numerical difference between the OAR dose resulting from Heuristic 2 and the DP
approach is not even visible when using two decimal places. Finally, we also simulate
the algorithm in [48] for comparison and notice that it is close to optimal as well, like
the other heuristics.
In Figure 2-5, we vary both the number of fractions N and the daily fraction size
deviations, and simulate the decrease in the OAR dose when using the optimal DP
approach. We use 20%, 50%, and 100% daily fraction size deviations, and 5, 30, and 60
fractions for N . This allows us to understand the benefit of adaptive fractionation in
hypo-, standard, and hyper-fractionation regimes. This, however, may not be entirely
accurate because we simply normalize the dose per fraction so that the same prescribed
dose P is met at the end of treatment, and we do not take into account the biological
effect of varying N . The error bars in Figure 2-5 correspond to one standard deviation,
as estimated from the simulation of 500 treatment runs. A larger number of frac-
tions and daily fraction size deviation result in more chances to capitalize on favorable
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Figure 2-5: Comparing adaptive fractionation in hypo-, standard, and hyper-
fractionated settings. We simulate the performance of just the optimal DP approach
through 500 treatment runs. The fraction size is adjusted when varying the number of
fractions N so that the same prescribed dose P is met at the end of treatment. The
error bars correspond to one standard deviation, as estimated from the results of the
500 runs. We find a larger decrease in dose to the OAR when using more fractions and
larger daily fraction size deviations.
anatomy, and therefore, result in more gain. We see bigger error bars when using larger
daily fraction size deviations due to the increased variation in the ability to capitalize
on favorable anatomy. On the other hand, we see smaller error bars when increasing
the number of fractions, which means the treatment outcome is more predictable; this
is because with a large number of fractions, laws of large numbers (from probability
theory) take effect. In summary, Figure 2-5 shows that the percentage decrease in the
dose to the OAR varies significantly (anywhere from 5 - 55%). But in general, we find
more gain when using a larger number of fractions and daily fraction size deviations.
As we see in Figure 2-6, the decrease in dose to the OAR is more pronounced when
we have a high probability of large tumor-OAR distances. We use three distributions,
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each corresponding to parameters of the beta distribution (p(s) = c · s1−α(1 − s)1−β,
where c is a normalization constant), and plot them in the right panel. As before,
we use 10 uniformly discretized values between 0 and 1 for the possible tumor-OAR
distances. In the left panel, for the Unfavorable distribution, the percentage decrease in
the OAR dose is minimal. On the other hand, there is a significant decrease in the OAR
dose for the Uniform and Favorable distributions. We conclude that when the OAR
tends to stay far away from the tumor, we see a larger decrease in dose to the OAR. In
such cases, favorable anatomies are frequent enough so that the DP approach is able
to make up for the small fraction sizes used for unfavorable anatomies. When allowing
a 100% daily fraction size deviations and using the Favorable distribution, there is at
least a 10% decrease in the OAR dose when comparing the optimal DP approach with
the algorithm in [48]. Here, the algorithm in [48] “believes” favorable anatomies will
be frequent enough over the course of treatment so that no matter what fraction size is
delivered in the initial fractions, it will be able to make up for the much more infrequent
unfavorable anatomies.
2.9 Convergence of Heuristic 1 to optimality as N →
∞
We analyze the asymptotic properties of Heuristic 1 (as a function of the number of
treatments, N). We find that the expected cost associated with Heuristic 1 converges
to the expected cost associated with the optimal DP algorithm as N → ∞, with
the discrepancy being of order O
(√
logN√
N
)
. The discussion in this section provides a
theoretical justification for Heuristic 1 and in some sense, convinces us of its “soundness”
as a solution approach. For our previous theoretical results, as mentioned in Remark 3,
we only required the Markov property to hold true for the sequence of patient anatomy
instances. The results in this section require however a stronger assumption, stated
next.
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Figure 2-6: Results from varying the motion probability distribution. In the right
panel, we show the three probability distributions used, each resulting from varying
parameters of the beta distribution. In the left panel, we show the average percentage
decrease (from 500 treatment runs) in dose to the OAR for each of these probability
distributions. For probability distributions in which the OAR tends to stay far away
from the tumor, there is a larger decrease in dose to the OAR, and the optimal DP
approach is at least 10% better than the other heuristics.
Assumption 2.9.1. The patient anatomy instances sk, for k = 1, 2, . . . , N , are inde-
pendent.
For our results to hold, we also need an additional assumption stated below to ensure
that the probability distribution is well-behaved. For this section, we use the probability
distribution ph(·) on h(sk) rather than p(·) on sk.
Assumption 2.9.2. The probability distribution of h(sk) is continuous, described by a
density ph(·), which is bounded above by a constant K (i.e., |ph(x)| ≤ K for all x).
We denote the expected cost associated with using the optimal DP approach and
Heuristic 1 by Cdp and Cheu1, respectively. We wish to show that |Cheu1 − Cdp| → 0 as
N →∞. We will simplify the mathematical analysis by finding a lower bound for Cdp
instead of using the DP algorithm directly. To find such a lower bound, consider the
fractionation problem when the sequence of costs h(sk), for k = 1, 2, . . . , N , are known
prior to treatment. The resulting expected cost, which we denote by C∗, is definitely
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smaller than Cdp. Hence, we must have C∗ ≤ Cdp ≤ Cheu1, where the last bound is
due to the optimality of the DP algorithm. The analysis below will involve showing
|Cheu1 − C∗| → 0 as N →∞, which will also imply |Cheu1 − Cdp| → 0.
Even though it may be inconsistent with prior notation, in this section, sk refers to
a random variable, not an observed or known quantity. We will relate the cost C∗ to
the empirical median MN , which we define below.
Definition 2.9.1. The empirical median MN satisfies FN(MN ) = 0.5, where the em-
pirical CDF FN is defined as
FN(x) =
1
N
N∑
k=1
I{h(sk)≤x}.
Here, I denotes the indicator random variable:
IA =

1, if event A occurs
0, otherwise.
In order to relate the empirical medianMN to C∗, we note that the event Dk = {h(sk) <
MN} consists of N/2 patient anatomies with the lower costs (assuming, for simplicity,
N is even). The event Dck then corresponds to those with the higher costs. Now, it is
clear that
C∗ = E
[
N∑
k=1
h(sk)
(
uIDk + uIDck
)]
. (2.12)
We can similarly relate Cheu1 to the true median M . We define the event Ak = {h(sk) <
M}, which consists of patient anatomies for which Heuristic 1 delivers u. In order to
incorporate the heuristic’s boundary conditions, we define the events Bk = {rk =
(N − k)u} and Ck = {rk = (N − k)u}. Finally, we can write
Cheu1 = E
[
N∑
k=1
h(sk)
(
uIAk∩Bck∩Cck + uIAck∩Bck∩Cck + uIBk + uICk
)]
.
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The empirical CDF FN(·) and empirical median MN are estimates of the true un-
derlying CDF F h(·) and true median M , respectively. Existing results in probability
theory prove the uniform convergence of FN (·) to F h(·) and also provide bounds on the
rate of convergence. In order to show the convergence of |Cheu1 − C∗| → 0, we will rely
on the convergence of the empirical median MN to the true median, M . The following
two lemmas show convergence in probability and convergence in the r-th mean of MN
to M , respectively.
Lemma 2.9.1. Assume a positive density in a small interval around the median M ,
i.e., ph(x) > 0 for x ∈ [M − γ,M + γ]. Then,
P(|MN −M | > ǫ) ≤

2e−2c
2Nǫ2, if 0 < ǫ ≤ γ
2e−2c
2Nγ2 , if ǫ > γ,
where c = min
x∈[M−γ,M+γ]
ph(x).
Proof. See Appendix 2.11.4.
Lemma 2.9.2. Assume a positive density in a small interval around the median M ,
as in Lemma 2.9.1. Then, the empirical median MN converges in the r-th mean to the
true median M as N →∞. Furthermore, as a function N , we have for r ≥ 1
E
[|MN −M |r] = O
([
logN
N
] r
2
)
.
Proof. See Appendix 2.11.5.
The cost C∗ uses the empirical median while Cheu1 uses the true median. Given the
nice convergence properties of the empirical median to the true one, it is reasonable to
relate the two costs and analyze convergence. The main difficulty lies in the boundary
conditions corresponding to the sets Bk and Ck in the definition of Cheu1. In the next
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lemma, we show that the probability of the sets Bk and Ck is small (exponentially
decreasing with N) for all but the last O
(√
N logN
)
fractions.
Lemma 2.9.3. For any a > 0, we have
max {P(Bk),P(Ck)} ≤ 1
Na
,
if k ≤ N − ⌊2√a
2
N logN⌋ − 1.
Proof. See Appendix 2.11.6.
Finally, we state the main result in the following theorem.
Theorem 2.9.4. Heuristic 1 is asymptotically optimal. That is, |Cheu1 − Cdp| → 0 as
N →∞. The rate of convergence is O
(√
logN√
N
)
.
Proof. See Appendix 2.11.7.
We have shown that Heuristic 1 is “sound” in the sense that it is optimal in the limit
as the number of treatments N is very large. Though the results in this section have
little impact on the practical applicability of any particular method, it provides some
theoretical insight.
2.10 Discussion and conclusions
Realistic implementation of the approaches described in this chapter require the follow-
ing:
1. The motion probability distribution p(·) must be known. One could in principle
collect and analyze population data, and assign probabilities corresponding to a
few anatomy scenarios. However, this may not be an accurate representation of a
patient-specific probability distribution. Updating the probability distribution as
the sequence of patient anatomy instances are observed could be a topic of future
research.
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2. Immediately before the delivery of a fraction, imaging information about the
patient anatomy must be available as well as reliable automatic contouring and/or
contour registration algorithms to process this information. This would be needed
in order to determine the favorability of the patient anatomy in any particular
day. We can be optimistic that such technology will be available in the near
future.
3. The OAR dose per unit dose to the tumor, h(sk), must be computable before the
delivery of each fraction. In order to speed up the computation, one may use the
same dose deposition matrix from the initial CT scan as an approximation and
determine the dose projected on the OAR in the new CT. We emphasize that this
model does not depend on using the OAR dose per unit tumor dose for h(sk); we
simply need a function h(sk) which tells us how favorable a particular anatomy
sk is.
Other assumptions of our model include the following:
1. One primary OAR is the basis for making decisions about the fraction size. Mul-
tiple OARs can be used, for example, by using for h(sk) a weighted combination
of the dose to each OAR per unit dose to the tumor. However, this does not
capture the true tradeoff between the various OARs because there is also gener-
ally an upper limit to the dose of each OAR. The model would better represent
the radiation therapy problem if, for example, the non-linear NTCP curves were
incorporated into the cost function. There is potential for further research work
here.
2. The prescribed dose to the tumor must be met exactly and is penalized with
an infinite cost. One may also consider using a penalty (e.g., quadratic) on the
deviation from the prescribed dose, which would possibly result in a “smoother”
optimal policy that does not pick the extreme fraction sizes.
3. Variations in the patient anatomy are dose-independent and random. In order
56
to incorporate systematic time varying trends (e.g., tumor shrinkage), we can re-
optimize the treatment plan (the dose profile) midway through treatment. Then,
we can use one of the adaptive fractionation methods in this chapter for the first
half of treatment assuming no systematic changes. For the latter half of treat-
ment, we would re-optimize the treatment plan, update the motion probability
distribution and/or escalate the prescribed dose if necessary, and restart the adap-
tive fractionation method. For other systematic offsets (e.g, patient setup errors),
we assume daily imaging modalities are accurate enough for correction.
4. When the daily fraction size deviations are not too large, the biological impact
of a varied fractionation scheme is negligible. It is likely that deviating 20% from
standard fractionation does not result in a major difference between physical dose
and biological dose [6]. Dose deviations of 50% and 100%, however, need further
study. Using large deviations and varied fractionation may require additional con-
siderations such as changes in the onset of early and late reactions. A biologically
based adaptive fractionation approach is given in [13].
Under our framework, it is possible to derive the algorithm in [48] and see that it is
a variant of the approximate DP approach known as open-loop feedback control (refer
to [4] for a description of such an approach). From the numerical results, we conclude
that the algorithm in [48] performs very close to optimal for almost all cases. However,
we do see that the DP approach performs about 10% better when allowing 100% daily
fraction size deviations and using a probability distribution that favors large tumor-
OAR distances. One difference in the way these algorithms would be used in practice
is that the DP approach involves an online table lookup, while the algorithm in [48]
requires solving a linear programming (LP) problem right before the delivery of every
fraction. Though a table lookup is quicker, solving a LP for this problem, where we are
simply searching for a scalar variable uk, is also very fast and can be done before each
fraction without much time overhead.
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Based on the linear-quadratic model of radiation effects, varying the fraction size
during the course of treatment while ensuring a fixed total prescribed dose leads to a
higher TCP [6]. One might argue that this benefit is neutralized by an increase in the
NTCP for the OAR. However, assuming that the OAR has an underlying motion, even
standard fractionation results in a different dose to the OAR from fraction to fraction.
Adaptive fractionation will lead to a more uniform dose to the OAR because a small
fraction size is delivered when the OAR-to-tumor dose ratio h(sk) is large (i.e., when
the tumor and OAR are close together), and vice versa. Further research can be done
to evaluate the biological benefit of varying the fraction size.
We have posed the adaptive fractionation problem in a theoretical framework and
have provided several solution methods. First, we used the DP algorithm to establish a
benchmark and to solve the problem exactly. This allowed us to show that the simple
heuristics proposed in this chapter were numerically near-optimal. One of these heuris-
tics only uses a statistic, such as the median or mean, rather than the entire probability
distribution. Such a policy can provide a quick way to estimate the best possible benefit
of using an adaptive fraction size in a realistic setting. We have demonstrated through
numerical simulations that we can expect a significant decrease in dose to the OAR
when: (i) we have a high probability of large tumor-OAR distances, (ii) we use many
fractions (as in a hyper-fractionated setting), and (iii) we allow large daily fraction size
deviations. We expect adaptive fractionation to be beneficial for disease sites in which
the OAR exhibits significant motion from day to day. Some examples include pelvic
cases such as rectal [59], prostate [83], and cervical [25] cancers.
2.11 Appendix: proofs
2.11.1 Proof of Lemma 2.5.1
Proof. From equation (2.3), we can see that Jk(rk, sk) = ∞ if (rk − uk) /∈ Fk+1 (since∫
S
p(s)Jk+1(rk−uk, s) ds =∞ if (rk−uk) /∈ Fk+1). Therefore, we can rewrite Equation
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(2.3) as
Jk(rk, sk) = min
uk∈Uk(rk)
(
ukh(sk) + Jk+1(rk − uk)
)
,
where Uk(rk) = {uk : u ≤ uk ≤ u, (rk − uk) ∈ Fk+1}. Using the definition of Fk+1 from
Equation (2.6), we see that
Uk(rk) = {uk : u ≤ uk ≤ u, (N − k)u ≤ rk − uk ≤ (N − k)u}
= {uk : max(u, rk − (N − k)u) ≤ uk ≤ min(u, rk − (N − k)u))}
= {uk : Bk(rk) ≤ uk ≤ Bk(rk)},
from which we can write Equation (2.7).
2.11.2 Proof of Theorem 2.5.2
Proof. We proceed by induction. For the base case, let k = N . It is clear that the
optimal decision in this last fraction, µ∗N(rN , sN), is equal to the remaining dose rN .
(Otherwise, we would incur an infinite penalty for not meeting the prescribed dose
exactly.) In this case, for any rN ∈ FN , JN(rN , sN) = rNh(sN ), which has the desired
continuous, non-decreasing, convex, and piecewise linear form. Now, assume that Jk+1,
for rk+1 ∈ Fk+1, also has this form as stated in the theorem. First, we prove convexity
of Jk in rk. Then, we prove the remaining properties of Jk along with the structure of
an optimal policy.
Step 1: Proof of convexity For any r1k, r
2
k ∈ Fk, we have
Jk
(
r1k + r
2
k
2
, sk
)
= min
u≤uk≤u
(
ukh(sk) + Jk+1
(
r1k + r
2
k
2
− uk
))
≤ ukh(sk) + Jk+1
(
r1k + r
2
k
2
− uk
)∣∣∣∣
uk=
µk(r
1
k
,sk)+µk(r
2
k
,sk)
2
,
where µk(rk, sk) = argmin
u≤uk≤u
[
ukh(sk) + Jk+1(rk − uk)
]
. Notice that the choice
µk(r
1
k
,sk)+µk(r
2
k
,sk)
2
for uk above is feasible (i.e., between u and u) because the condition u ≤ µk(rk, sk) ≤ u
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is always true. We also claim that (r1k−µk(r1k, sk)), (r2k−µk(r2k, sk)) ∈ Fk+1. To see this
is true, suppose (r1k − µk(r1k, sk)) /∈ Fk+1. Then,
Jk(rk, sk) = µk(r
1
k, sk)h(sk) + Jk+1(r
1
k − µk(r1k, sk))
= µk(r
1
k, sk)h(sk) +∞
= ∞,
which contradicts the optimality of µk. Hence, (r
1
k−µk(r1k, sk)), (r2k−µk(r2k, sk)) ∈ Fk+1
must be true. Using this fact and the convexity of Jk+1(rk+1) in rk+1 (taking expectation
preserves convexity), we have
Jk
(
r1k + r
2
k
2
, sk
)
≤
(
µk(r
1
k, sk) + µk(r
2
k, sk)
2
)
h(sk)
+Jk+1
(
r1k − µk(r1k, sk)
2
+
r2k − µk(r2k, sk)
2
)
≤
(
µk(r
1
k, sk) + µk(r
2
k, sk)
2
)
h(sk)
+
1
2
Jk+1
(
r1k − µk(r1k, sk), w
)
+
1
2
Jk+1
(
r2k − µk(r2k, sk)
)
=
1
2
Jk
(
r1k, sk
)
+
1
2
Jk
(
r2k, sk
)
.
Therefore, Jk(rk, sk) is convex in rk (midpoint convexity implies convexity), and the
result follows.
Step 2: Proof of remaining properties We assume u = 0 and u = 1 for simplicity.
For the general case, the same arguments below can be used, with more bookkeeping
and algebra. The proof below uses similar types of arguments as the proof for the
inventory control problem in [4]. From the DP Algorithm, we have
Jk(rk, sk) = min
0≤uk≤1
[
ukh(sk) + Jk+1(rk − uk)
]
. (2.13)
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By introducing the variable y = rk − uk, we can rewrite (2.13) as
Jk(rk, sk) = min
rk−1≤y≤rk
[Gk(y, sk)] + rkh(sk), (2.14)
where Gk(y, sk) = −yh(sk) + Jk+1(y). From the previous step, we have that Jk+1(y) is
convex in y (taking expectation preserves convexity). Thus, the function Gk is convex
in y because it is a sum of two convex functions in y: −yh(sk) and Jk+1(y). Let us
suppose that the unconstrained minimum over y of Gk(y, sk) exists and denote it as
Ak(sk):
Ak(sk) = argmin
y∈R
Gk(y, sk).
Since Jk+1(y) is infinite for y /∈ Fk+1, we can simplify the minimization by restricting
y to be in Fk+1:
Ak(sk) = argmin
y∈Fk+1
Gk(y, sk).
Now, in the induction, we assume Jk+1, for rk+1 ∈ Fk+1, is continuous and piecewise
linear with breakpoints at integers between 0 and N − k. Therefore, Gk(y, sk) also has
the same form in y. Because we are minimizing a continuous, convex function in y over
Fk+1 (a compact, convex set), it follows that the minimizer Ak(sk) exists. Furthermore,
due to the particular piecewise linear form of Gk in y, Ak(sk) can be restricted to be
an integer between 0 and N − k without loss of optimality. Finally, incorporating the
constraint r − 1 ≤ y ≤ r, we have an optimal solution for (2.14):
y =

rk − 1, if rk ≥ 1 + Ak(sk)
Ak(sk), if Ak(sk) ≤ rk < 1 + Ak(sk)
rk, if rk < Ak(sk).
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Using the reverse transformation uk = rk − y, we have
µk(rk, sk) =

1, if rk ≥ 1 + Ak(sk)
rk − Ak(sk), if Ak(sk) ≤ rk < 1 + Ak(sk)
0, if rk < Ak(sk),
which has the desired form in (2.8). Substituting this policy into the DP equation, we
have
Jk(rk, sk) =

h(sk) + Jk+1(rk − 1), if rk ≥ 1 + Ak(sk)
(rk − Ak(sk))h(sk) + Jk+1(Ak(sk)), if Ak(sk) ≤ rk < 1 + Ak(sk)
Jk+1(rk), if rk < Ak(sk).
(2.15)
Using the properties of piecewise linearity of Jk+1 in rk+1 and integer Ak(sk), it
is clear from (2.15) that Jk in rk is piecewise linear with breakpoints between 0 and
N−k+1. Furthermore, assuming Jk+1 is continuous and non-decreasing in rk+1, we can
see from (2.15) that Jk is also continuous and non-decreasing in rk. We have completed
the induction.
2.11.3 Proof of Corollary 2.5.3
Proof. We assume u = 0 and u = 1 for ease in exposition. We use the DP algorithm
from Lemma 2.7:
Jk(rk, sk) = min
Bk(rk)≤uk≤Bk(rk)
(
ukh(sk) + Jk+1(rk − uk)
)
. (2.16)
From Theorem (2.5.2), it follows that Jk+1(rk−uk) continuous, non-increasing, convex,
and piecewise linear in uk with breakpoints at rk − i, where i is an integer between
0 and N − k. Note that there is at most a single breakpoint in between Bk(rk) and
Bk(rk). We will assume that uk = rk − i∗ is this breakpoint, where i∗ is between 0 and
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N−k. The derivative of the objective in (2.16) is h(sk) plus a non-decreasing piecewise
constant function. It follows that if h(sk) is very large, the optimum would be the
smallest deliverable dose Bk(rk). Similarly, if h(sk) is very small, the optimum would
be the largest deliverable dose Bk(rk). In between these two cases, the optimum would
be rk − i∗, which allows the subderivative of the objective in (2.16) to be zero. This
results in the desired form of an optimal policy. We can also use the above argument
for a general u and u.
2.11.4 Proof of Lemma 2.9.1
Proof. Since c is the minimum slope of F (x) in the interval [M−γ,M+γ], for 0 < ǫ ≤ γ,
we have
F (M − ǫ) ≤ F (M)− cǫ
and
F (M + ǫ) ≥ F (M) + cǫ. (2.17)
Note that since we have a continuous distribution, F (M) = 1/2. Also, FN(MN ) = 1/2,
by definition. Now we will show that if |MN −M | > ǫ, then |F (MN)− FN(MN )| > cǫ.
If MN −M > ǫ, then
F (MN) > F (M + ǫ) (2.18)
≥ F (M) + cǫ (2.19)
= FN (MN) + cǫ,
which implies F (MN) − FN(MN ) > cǫ as desired. In (2.18), we use the monotonicity
property of the distribution F (·), and in (2.19), we use Equation (2.17). Similarly, if
63
MN −M < −ǫ, then:
F (MN) < F (M − ǫ)
≤ F (M)− cǫ
= FN(MN )− cǫ,
and therefore, F (MN)− FN (MN) < −cǫ. We have shown that if |MN −M | > ǫ, then
|F (MN) − FN (MN)| > cǫ. The first inequality below makes use of this property. We
have
P(|MN −M | > ǫ) ≤ P(|F (MN)− FN(MN )| > cǫ)
≤ P(sup
x
|FN(x)− F (x)| > cǫ)
≤ 2e−2c2Nǫ2, (2.20)
where in (2.20), we use the Dvoretzky-Kiefer-Wolfowitz inequality.
For ǫ > γ,
P(|MN −M | > ǫ) ≤ P(|MN −M | > γ)
≤ 2e−2c2Nγ2 ,
where the last inequality follows from the result for the case ǫ ≤ γ.
2.11.5 Proof of Lemma 2.9.2
Proof. We use the definition of the expected value that makes use of the cumulative
distribution and write for 0 < ǫ ≤ γ (where γ is the distance from the median M within
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which ph(·) has positive density as defined in Lemma 2.9.1) and r ≥ 1:
E
[|MN −M |r] = r ∫ 1
0
xr−1 P(|MN −M | > x) dx
= r
∫ ǫ
0
xr−1 P(|MN −M | > x) dx+ r
∫ 1
ǫ
xr−1 P(|MN −M | > x) dx
≤ ǫr + r
∫ 1
ǫ
xr−1 P(|MN −M | > x) dx
≤ ǫr + 2re−2c2Nǫ2
∫ 1
ǫ
xr−1 dx (2.21)
= ǫr
(
1− 2e−2c2Nǫ2
)
+ 2e−2c
2Nǫ2,
where in (2.21), we use Lemma 2.9.1 and the fact that the exponential function is
monotonically decreasing in x. Since the above bound holds for 0 < ǫ ≤ γ, we can take
the minimum of the right-hand side over this range. Now, since we are interested in
the limiting behavior as N →∞, we can choose to analyze the case for large N so that[
mlogN
N
] 1
2 ≤ γ, where m is some positive constant. In this case, we have
0 ≤ E[|MN −M |r] ≤ min
0<ǫ≤γ
[
ǫr
(
1− 2e−2c2Nǫ2
)
+ 2e−2c
2Nǫ2
]
≤
[
ǫr
(
1− 2e−2c2Nǫ2
)
+ 2e−2c
2Nǫ2
]
ǫ=[mlogNN ]
1
2
= m
r
2
[
logN
N
] r
2
(
1− 2
N2c2m
)
+
2
N2c2m
Since we can take m to be any positive constant in the above bound, we select large m
such that the right-hand side is O
([
logN
N
] r
2
)
. Thus, we have
E
[|MN −M |r] = O
([
logN
N
] r
2
)
,
as desired.
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2.11.6 Proof of Lemma 2.9.3
Proof. Below, we use Hoeffding’s inequality:
P(Bk) = P(that of the first k fractions, at least N/2 were delivered u)
= P
(
k∑
i=1
IAc
k
≥ N
2
)
= P
(
k∑
i=1
(
IAc
k
− 1
2
)
≥ N
2
− k
2
)
≤ exp
[
−2 (N/2− k/2)2
k
]
.
By similar argument, we can show
P(Ck) ≤ exp
[
−2 (N/2− k/2)2
k
]
.
Now, for k ≤ N − ⌊2√a
2
N logN⌋ − 1, we have
max {P(Bk),P(Ck)} ≤ exp
[
−2 (N/2− k/2)2
k
]
≤ exp
[
−2 (N/2− (N − ⌊2√a
2
N logN⌋ − 1)/2)2
N − ⌊2√a
2
N logN⌋ − 1
]
≤ exp
[
−2 ((⌊2√a
2
N logN⌋+ 1)/2)2
N
]
≤ exp
[
−2 (√a
2
N logN
)2
N
]
=
1
Na
.
2.11.7 Proof of Theorem 2.9.4
Proof. For convenience, we define up and up to represent the percentage deviation for
the upper limit and the lower limit of the tumor dose, respectively. These can be related
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to the already defined quantities by the equations u = up(P/N) and u = up(P/N). We
first bound Cheu1:
Cheu1 = E
[
N∑
k=1
h(sk)
(
uIAk∩Bck∩Cck + uIAck∩Bck∩Cck + uIBk + uICk
)]
≤ E
[
N∑
k=1
h(sk)
(
uIAk + uIAck + uIBk + uICk
)]
.
Now, using Equation (2.12) for C∗ and the above bound for Cheu1, we see that Cheu1−C∗ ≤
V1 + V2, where
V1 =
N∑
k=1
E
[
h(sk)
(
u (IAk − IDk) + u
(
IAc
k
− IDc
k
))]
and
V2 =
N∑
k=1
E [h(sk) (uIBk + uICk)] .
We can bound these quantities:
V1 =
N∑
k=1
E
[
h(sk)
(
u (IAk − IDk) + u
(
IAc
k
− IDc
k
))]
=
N∑
k=1
E
[
E
[
h(sk)
(
u
(
IAk − I(ANk )c
)
+ u
(
IAc
k
− I(AN
k
)c
))
|MN
]]
(2.22)
=
N∑
k=1
E
[
u
∫ M
MN
xph(x) dx+ u
∫ MN
M
xph(x) dx
]
= P E
[
up
∫ M
MN
xph(x) dx+ up
∫ MN
M
xph(x) dx
]
≤ P (up − up)E [∣∣∣∣∫ M
MN
xph(x) dx
∣∣∣∣]
≤ P (up − up)K E [|MN −M |] (2.23)
= O
(√
logN√
N
)
, (2.24)
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where we use the law of iterated expectations in (2.22), Assumption 2.9.2 in (2.23), and
Lemma 2.9.2 in (2.24). We also have
V2 =
N∑
k=1
E [h(sk) (uIBk + uICk)]
= E [h(sk)]
N∑
k=1
E [uIBk + uICk ] (2.25)
= E [h(sk)]
N∑
k=1
[uP(Bk) + uP(Ck)]
≤ P E [h(sk)] (up + up)
N
N∑
k=1
max {P(Bk),P(Ck)}
≤ P E [h(sk)] (up + up)
N
N−⌊2
√
a
2
N logN⌋−1∑
k=1
1
Na
+O
(√
N logN
) (2.26)
≤ P E [h(sk)] (up + up)
N
[
1
Na−1
+O
(√
N logN
)]
= O
(√
logN√
N
)
,
where we use independence (Assumption 2.9.1) in (2.25) and Lemma 2.9.3 in (2.26).
Now,
0 ≤ Cheu1 − Cdp
≤ Cheu1 − C∗
≤ V1 + V2
= O
(√
logN√
N
)
.
Since lim
N→∞
√
logN√
N
= 0, it is clear |Cheu1 − Cdp| → 0 as N →∞.
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Chapter 3
Adaptive fractionation and
treatment plan selection from a
plan library
3.1 Introduction
In this chapter, we investigate the benefit of both adaptive fractionation and treatment
plan selection from a plan library. The presented methods are tested on three prostate
datasets, each consisting of a simulation CT and CTs for 38 fractions. We find that the
spatial adaptation offered by selection from a plan library and the temporal adaptation
from varying the fraction size can result in significant improvement in dose distribution
quality metrics.
Adaptive fractionation therapy was first introduced in [13,48]. The main idea is to
deliver a larger fraction size when the dose ratio (dose to OAR per unit dose to tumor)
is small and vice versa. We use the dose to the anterior rectum as the primary metric
for comparison; this is because it is the main dose-limiting organ in prostate cancer.
We investigate the benefit of the dynamic programming (DP) approaches presented
in [13,65] using patient datasets, which has not been studied before. We are particularly
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interested in prostate cancer because of its low α-β ratio [51] and hence sensitivity to
fractionation. We believe this property of prostate cancer particularly makes adaptive
fractionation beneficial.
The purpose of this work is to develop novel adaptive treatment methods that avoid
or at least alleviate the required quality assurance (QA) procedures when a treatment
plan is adapted. The approach we take is to build and select from a library of physician
pre-approved treatment plans, and make quick modifications by changing the fraction
size based on the patient anatomy-of-the-day. We assume imaging information is ob-
tained before the delivery of each fraction; with recent technological developments such
as the CBCT, this assumption is reasonable. We assume that it is possible to automat-
ically propagate contours [12] from the simulation CT. In some sense, a plan library is a
hybrid approach, using both oﬄine and online ART. The oﬄine component is the gen-
eration of the set of treatment plans, and the online component is the selection based
on imaging information before the delivery of a fraction. The benefit of a hybrid oﬄine
and online approach has been previously illustrated [45]. The concept of a plan pool for
prostate cancer has also been discussed before in [46]. Still, the dosimetric benefits of
such approaches need further investigation. In this chapter, we propose both adaptively
choosing the fraction size and selecting from a plan library.
In Section 3.2, we discuss in detail the contributions of this chapter. In Section 3.3,
the model, formulation, and solution approach are presented. Further discussion about
the estimation of the dose ratio probability distribution and generation of a plan library
is also provided. In Section 3.4, we present results from using adaptive fractionation
and treatment plan selection on prostate datasets.
3.2 Contributions
We quantify the benefit of temporal adaptation by varying the fraction size and spatial
adaptation by selecting a plan from a pre-approved plan library. Specifically, we:
1. suggest an approach for both adapting the fraction size and selecting a treatment
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plan from a plan library. For adaptive fractionation, we refer to the DP approaches
described in [13,65] and also in Chapter 2. For treatment plan selection, we choose
a plan which results in the smallest dose ratio (also smallest dose in the OAR) as
long as it provides sufficient tumor coverage.
2. provide an approach to estimate the dose ratio probability distribution from his-
torical datasets. An approximate DP approach is suggested to incorporate an
updated probability distribution over the course of treatment.
3. use three prostate datasets and find that adaptive fractionation is beneficial when
using the BED model and not so much when using a physical dose model. This
is especially the case because prostate cancer has a small α-β ratio and is very
sensitive to fractionation.
4. propose a new type of fractionation scheme, which we name adaptive hypofrac-
tionation. The idea is to wait for the appropriate opportunity to deliver a large
fraction size. Computational experiments suggest that such an approach can be
advantageous because it results in reduced dose to the OAR and shortens the
number of days of treatment in comparison to conventional fractionation. Al-
though the standard hypofractionation does better for the three patient datasets
we used, it is potentially beneficial and requires further investigation.
5. find that in some cases, when the assumed dose ratio probability distribution
is different from the true one, the benefit of adaptive fractionation is reduced.
However, the described approach of updating the probability distribution and
using an approximate DP approach results in almost the same gain as if the true
distribution were known.
6. find that selection from a plan library together with adaptive fractionation has
significant benefit.
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3.3 Formulation and methods
In Subsection 3.3.1, we formulate the adaptive fractionation and treatment plan selec-
tion problem. The proposed solution method decouples the problem by first choosing
the fraction size based on a fixed treatment plan and second, selecting the best plan
for the observed patient anatomy. In Subsection 3.3.2, we use the notion of equivalent
uniform dose (EUD) as a metric for measuring the dose to the OAR and tumor. In
Subsection 3.3.3, we describe an approach to estimate the probability distribution of
the dose ratio from historical data. An approximate DP approach is described to han-
dle the case when the dose ratio probability distribution is updated over the course of
treatment. In Subsection 3.3.4, we discuss the generation of treatment plans and a plan
library.
3.3.1 Model, formulation, and solution approach
In principle, given bounds on the fraction size each day and a library of treatment plans,
we would like to simultaneously optimize the fraction size and select a treatment plan.
We are interested in using the dose ratio (dose to the OAR per unit dose to the tumor)
as such a measure of the favorability of a patient anatomy. Yet, estimation of the
probability distribution of these dose ratios is not straightforward, especially because
the ratios will differ based on the choice of the treatment plan. We, therefore, choose
to decouple the two problems: first, select the fraction size assuming a fixed nominal
plan, using an estimated probability distribution for the dose ratios, and second, select
the treatment plan assuming a standard dose fraction.
We now introduce the necessary notation. Let N be the number of fractions and
P be the total prescribed dose to the tumor. We denote by hk the dose ratio in the
kth day as observed from the patient anatomy of the day. The probability distribution
p(·) of the dose ratio hk can be estimated from patient datasets. We assume that hk is
observed just before the delivery of the kth fraction; this can be obtained from imaging
modalities such as CBCT together with automatic contouring tools. We denote by
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S the set of possible values of hk. We define rk to be the remaining prescribed dose
or biological effective dose (BED) left to deliver to the tumor in the kth and future
fractions. We can determine the fraction size uk in the kth fraction based on the
remaining dose rk and dose ratio hk. Thus, rk and hk represent the state of the system.
The dynamics of the system are described by the equations rk+1 = f(rk, uk), where
the form of f(rk, uk) depends on whether we are using physical dose or BED, with r1
initialized to the prescribed dose P , and hk ∼ p(·), for k = 1, 2, . . . , N . For a physical
dose model, we would have f(rk, uk) = rk − uk, and for a BED model, we would
have f(rk, uk) = rk − uk
(
1 + uk
[α/β]T
)
, where [α/β]T is the α-β ratio, a tissue specific
parameter of the tumor.
For the fractionation problem, we are interested in minimizing the expected total
dose or BED in the OAR. We would like to ensure that the prescribed dose to the tumor
is met with certainty, and that the fraction size for each day is within a lower bound,
u, and an upper bound, u. To solve the fractionation problem, we use the dynamic
programming approaches presented in [13, 65]. The DP algorithm is given below:
JN+1(rN+1, hN+1) =
 0, if rN+1 = 0,∞, otherwise,
Jk(rk, sk) = min
u≤uk≤u
(
g(uk, hk) +
∫
S
p(h)Jk+1(rk − uk, h) dh
)
, (3.1)
for k = N,N − 1, . . . , 1, where p(·) is the distribution of hk+1. In the above equations,
a cost of g(uk, hk) is incurred in each fraction. This could represent for example the
dose to the OAR, in which case g(uk, hk) = ukhk. Or, it could represent the BED in
the OAR, for which g(uk, hk) = ukhk
(
1 + ukhk
[α/β]O
)
, where [α/β]O is the α-β ratio of
the OAR. Further details about this dynamic programming approach can be found in
Chapter 2 and in references [13, 65].
For the treatment plan selection problem, in the kth fraction, we choose the plan
that results in the smallest dose ratio hk for the observed patient anatomy assuming
the target coverage is satisfied. This type of selection is myopic in that it does not
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consider the future cost of selecting a treatment plan. This is in direct contrast with
the discussed fractionation problem, where we choose a fraction size based on both the
current cost and the resulting expected future cost. Yet, we think this approximation
of selecting a treatment plan based only on the observed anatomy of the day is a good
one. Let the control lk be the plan we choose to deliver in the kth fraction. The control
lk is selected from the set {1, 2, . . . , Lk}, which represents our plan library (either pre-
selected or continually updated). Let the cost vector hk(l) represent the dose per unit
Gy delivered to the OAR when using the lth treatment plan for the patient geometry
in the kth day. Mathematically in the kth fraction then, we solve
minimize
lk∈{1,2,...,Lk}
hk(lk)
subject to dose to tumor voxels ≥ P
N
.
(3.2)
In summary, we choose to solve the fractionation and plan selection problems by de-
coupling them. We propose to solve the fractionation problem by using a dynamic
programming method previously introduced in [13, 65]. For the treatment plan selec-
tion problem, we choose the plan that results in the smallest dose ratio hk for the
observed patient anatomy assuming that the target coverage is satisfied.
3.3.2 Equivalent uniform dose and biological effective dose
In the above formulations, it was assumed that a homogeneous dose is delivered to both
the tumor and the OAR. In practice, however, the OAR actually receives a non-uniform
dose distribution. Thus, the question of interest is how we can convert a non-uniform
dose in the OAR to the dose ratio hk for a given patient anatomy. Here, we use the
concept of EUD [56], which allows us to convert a non-uniform dose to an equivalent
uniform one. Given a dose distribution di, for which i indexes the set of voxels in the
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OAR denoted O, the EUD is defined as
EUD(a) =
(
1
|O|
∑
i∈O
dai
)1/a
,
where |O| is the number of voxels in the OAR and a is an exponent dependent on the
OAR considered. For example, a = 1 represents the mean dose and would be a good
choice for a parallel organ like the lung. For a serial organ, the max dose in the dose
distribution becomes more important, and thus, a large value of a would be appropriate.
For some organs, as in the prostate case, the organs are neither parallel nor serial, in
which case an appropriate choice would be somewhere in between the two extremes.
The EUD could also be a good measure of target coverage when a non-uniform dose is
delivered to the tumor. In such cases, choosing a large enough negative value, such as
a = −20, provides a good measure of dose to the tumor.
For the fractionation problem formulation, the cost incurred each day is g(uk, hk),
which represents either the physical dose or the BED in the OAR. Due to the non-
uniform dose in the OAR, we calculate the dose ratio hk as the EUD in the OAR
divided by the dose per fraction to the tumor, which is typically 2 Gy. Thus, given
that we are using the physical dose model, g(uk, hk) actually represents the EUD in
the OAR in the kth fraction. In this case, we are minimizing the sum of the EUD in
the OAR over all fractions, which is not the same as the total EUD in the OAR at the
end of treatment. Even though the total EUD in the OAR may be a more meaningful
quantity, it also requires that we know exactly how much dose is delivered to each voxel
at the end of treatment. Measuring this total dose requires deformable registration
tools. We choose, however, not to use this approach because such methods are not
always reliable. We also approximate the BED in each fraction by using the EUD and
summing the BED over all fractions. These are the metrics we choose to use later in
this chapter to judge the effectiveness of adaptive treatments.
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3.3.3 Estimation of dose ratio probability distribution
For the fractionation problem, we would like to estimate the probability distribution of
the dose ratio hk using historical datasets. Since the dose ratios are highly dependent
on the treatment plan, it is only reasonable to use data obtained from the same disease
site and under similar treatment plans. We choose to assign probability mass to a fixed
number of possible dose ratios. Suppose we would like to estimate the probability of
m possible choices of dose ratios within some bounds h and h. We split the interval
[h, h] into m intervals of equal size and denote by hi the dose ratio corresponding
to the midpoint of those intervals. Thus, the value under this ith scenario is hi =
h+ h−h
m
(i− 1/2). To each of these dose ratios, we associate a corresponding probability
pi. A simple way to determine pi from historical datasets is to count the number of
occurrences of the dose ratio h in the interval
[
h+
h− h
m
(i− 1) , h+ h− h
m
i,
]
,
and divide by the total number of measurements m. In summary, we can determine
the probability of the dose ratios from historical datasets by using the formula
pi =
number of occurrences of ith dose ratio in m measurements
m
.
Even with a reasonable estimate of the probability distribution based on historical
data, it is still likely that population data will not be an accurate representation of the
patient-specific distribution. It is more appropriate, therefore, to update the probability
distribution over the course of treatment. In the kth fraction, we would like to use an
updated version of the probability distribution using the history of past dose ratios,
h1, h2, . . . , hk. In this case, our state must include not only the current dose ratio,
hk, in the kth fraction but also the history of past dose ratios. We define the history
state vector, Ik = (q
1
k, q
2
k, . . . , q
m
k ), where q
i
k is the number of occurrences of the ith
dose ratio in k treatment fractions. We denote the associated conditional probabilities
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p(hk|Ik) by pk = (p1k, p2k, . . . , pmk ) for each of the possible dose ratios {h1k, h2k, . . . , hmk }
in the kth fraction. We would like to update our prior knowledge from historical data,
which is captured by the estimated distribution pi, using the additional information
from k patient anatomy instances. One way to update to the conditional distribution
is through the formula:
pik =
crp
i + qik
cr + k
,
where cr is a concentration parameter. The parameter cr weighs our prior beliefs about
the probability of each scenario. A larger value of cr would put a higher weight on our
estimated probability distribution from historical data.
We now discuss a DP approach when updating the probability distribution over the
course of treatment. With the terminal condition ensuring that the prescribed dose is
met, ideally we would like to run the DP algorithm with an augmented state vector:
Jk(rk, Ik) = min
u≤uk≤u
(
g(uk, hk) +
m∑
i=1
pikJk+1(rk − uk, Ik+1)
)
for k = N,N − 1, . . . , 1, where Ik+1 is updated by incrementing the appropriate dose
ratio scenario in Ik. The above cost-to-go function Jk is defined on a state space of
dimension m + 1, which could still be computationally expensive if the number of
possible dose ratios is large. A simplification which can result in a faster but effective
algorithm is approximating Jk+1 by re-running the DP algorithm assuming the updated
probability distribution pk+1 for the remaining treatment days. We denote this cost-
to-go function with an updated probability distribution as J˜k+1. Thus, we have an
approximate DP algorithm
Jk(rk, Ik) ≈ min
u≤uk≤u
(
g(uk, hk) +
m∑
i=1
pikJ˜k+1(rk − uk, hi)
)
where the function J˜k+1 above is the cost-to-go function resulting from using the original
DP algorithm (3.1) assuming the updated probability distribution pk+1. To use this
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approximate algorithm, the DP algorithm with time horizon N − k− 1 needs to be run
in real time before the delivery of the kth fraction.
3.3.4 Generation of a plan library
We would like to solve an IMRT problem that provides a tradeoff between target cover-
age and healthy organ sparing. There are a number of ways to formulate the problem,
including linear/quadratic and other nonlinear formulations (see [69] for various ap-
proaches). Here, we choose to minimize the weighted sum of mean doses to the relevant
OARs and ensure a prescribed dose P/N to the tumor. We define mi, for i = 1, 2, . . . , 6,
to be the mean dose to the relevant OARs (see Table 3.1). Let di be the dose to the
ith voxel (i.e., individual points on the patient anatomy), and let T be the set of target
voxels (including margin expansion of the tumor volume). Mathematically, we solve
the following problem in order to determine the treatment plan from the simulation
CT:
minimize
{di≥0}
1
6
6∑
i=1
mi
subject to
P
N
≤ di ≤ 1.12P
N
, i ∈ T ,
di ≤ 1.12P
N
, i /∈ T ,
m1 ≤ P
N
,
mj ≤ 0.8P
N
, j = 2, 3, . . . , 6.
(3.3)
Though it is not included in the above formulation, we actually optimize the beam
intensities (beamlets) delivered from various angles rather than the dose distribution
denoted by di. We can convert the optimization problem by simply adding the con-
straints d = Dx and x ≥ 0, where D is the dose deposition matrix, d is a vector of
doses to voxels, and x is a vector of beamlets.
In order to adapt the treatment from day to day, we choose to create a library of
plans. Depending on the anatomy observed before treatment, a plan is selected from
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Table 3.1: Summary of notation for treatment plan optimization.
Notation Definition
m1 mean dose to anterior rectum
m2 mean dose to posterior rectum
m3 mean dose to bladder
m4 mean dose to left femoral head
m5 mean dose to right femoral head
m6 mean dose to skin
di dose to ith voxel
T set of tumor voxels including margin
P prescription dose over entire treatment
N number of treatment fractions
this library. Our purpose is to illustrate the benefit of using such a plan library. In
this chapter, we generate 2 plans by changing the volume consisting of target voxels:
CTV+2mm and CTV+5mm. These plans have different size margins (2mm and 5mm,
respectively) that are uniformly expanded around the clinical target volume (CTV),
which is the tumor volume visible in the CT. It is reasonable to assume that a conven-
tional plan for prostate cancer uses a 5mm margin, i.e. the second plan CTV+5mm in
our plan library.
3.4 Results from prostate cancer datasets
In Subsection 3.4.1, we provide details of how the plan library is generated and the
dose ratio probability distribution estimated. We discuss results from using adaptive
fractionation on prostate datasets using a physical dose model and the BED model
in Subsections 3.4.2 and 3.4.3, respectively. We discuss the benefit of updating the
probability distribution over the course of treatment in Subsection 3.4.4. Finally, in
Subsection 3.4.5, we discuss results from using a plan library.
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3.4.1 Treatment plan optimization and probability distribu-
tion estimation
We study three prostate cancer patient datasets, each consisting of a simulation CT
image for optimizing a treatment plan and 38 CT images for each of the fractions.
The target and the relevant organs in all of the CT images were contoured by either a
physician or a resident under the supervision of a physician [83]. The target was the
tumor volume plus the margin expansion for addressing uncertainties.
For each patient, we generate two plans; one consisting of a 2 mm margin expansion
and the other a 5 mm expansion. We use seven 6 MV equispaced and coplanar photon
beams. The dose deposition matrix is computed by the quadratic infinite beam (QIB)
pencil-beam dose calculation algorithm in CERR 3.0 beta 3 (refer to [17]). The voxel
resolution grid is 1.96 x 1.96 x 5 mm3 for all three simulation CTs. The total number of
beamlets for patient 1, 2, and 3 are 280, 325, and 251, respectively. These only include
beamlets that contribute to the dose in the target. The total number of voxels per
structure for each patient is given in Table 3.2. The number of voxels in the bladder,
femoral heads, and skin were downsampled by a factor of 4, 8, and 16, respectively.
We solve the formulation (3.3) with P = 76 Gy and N = 38 using Matlab’s built-
in linprog function (large-scale interior point algorithm). The average solution time
for each treatment plan was about 5 minutes. For patient 3, the constraints in the
formulation (3.3) were too stringent; thus, we relaxed the upper bound on all voxels
from 1.12P/N to 1.2P/N , and solved this relaxed problem instead.
For patient 1, we generated the DVH curves for the CTV and anterior rectum
in the 2 mm and the 5 mm margin plan (Figure 3-1). We see that the dose to the
primary OAR, the anterior rectum, is significantly lower in the 2 mm margin plan
when compared to the 5 mm one; this makes sense because a smaller target volume
means fewer constraints for the optimization solver. Thus, we can conjecture that for
the 2 mm and 5 mm plans, the solution to (3.2) simply results in choosing the plan
with the smallest margin as long as target coverage is ensured.
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Figure 3-1: Dose volume histogram (DVH) for generated treatment plans. The CTV
DVH curves for both the 2 mm and 5 mm margin plans are very close and indistin-
guishable on the above plot. Note that the anterior rectum DVH curve for the 2 mm
margin plan is entirely below the one for the 5 mm plan.
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Table 3.2: Number of voxels for each patient. The bladder, femoral heads, and skin
voxels were downsampled by a factor of 4, 8, and 16, respectively. Any voxels not
influenced by beamlets were removed.
Number of voxels
Structure Patient 1 Patient 2 Patient 3
2 mm PTV 2,101 2,603 2,913
5 mm PTV 3,102 3,562 4,202
anterior rectum 1,142 751 668
posterior rectum 1,121 971 695
bladder 668 491 231
left femoral head 67 69 67
right femoral head 73 61 72
skin 2,487 2,729 1,807
total 10,761 11,237 10,655
For solving the fractionation problem, we need an estimate of the probability distri-
bution of the dose ratio. We only use a single treatment plan, in our case the 5 mm plan,
to estimate such a distribution. For the CT image of every fraction, we re-calculate
the dose deposition matrix using CERR’s QIB pencil beam algorithm as before. With
the new dose deposition matrix for each fraction, the optimized beamlets from the sim-
ulation CT were used to compute the dose distribution on the patient anatomy. The
patient setup was assumed to be perfect and the isocenter of the target, given by the
center of mass of the target volume, was aligned exactly for every fraction. To compute
the dose ratio (dose to the primary OAR of interest divided by dose to tumor), we use
the formula h = EUD(a)/2, where EUD(a) is the EUD with an exponent a and the two
in the denominator comes from 2 Gy per fraction dose to the target. Possible choices
for the exponent here could be 1, which is the mean dose, or larger values for a more
serial organ. The primary OAR of interest in the prostate case is the anterior rectum,
which is not completely parallel or serial; we choose a = 3 for this OAR. We assume
that the dose ratio lies somewhere between 0.5 and 1 (i.e., h = 0.5 and h = 1). We set
the number of possibilities m to be 10. For each patient, we count the fraction of dose
ratios falling within the corresponding intervals of even length, and determine the true,
82
Figure 3-2: Estimation of true dose ratio probability distribution for each of the three
patients. We discretized the possible dose ratios into 10 intervals in the range 0.5-1.
Note that patient 3 has less variation than the other two patients due to less day to
day organ motion.
discretized probability distribution of the dose ratios (Figure 3-2). When solving the
fractionation problem, if we use this true distribution for each of the patients, we will
be able to quantify the best possible benefit of using an adaptive fraction size.
3.4.2 Fractionation using physical dose model
We consider solving the adaptive fractionation problem using a physical dose model.
That is, the state rk represents the physical remaining dose and the dynamics equation
satisfies rk+1 = f(rk, uk) = rk−uk. The cost per day is the dose resulting from delivering
a fraction size uk, i.e. g(uk, hk) = ukhk. For structural properties of an optimal policy,
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refer to Chapter 2 or the paper [65]. As mentioned before, we will use only a single
plan, in our case the 5 mm margin one, to determine the fraction size. The metric for
comparison will be the sum of the EUD in the anterior rectum, our primary OAR, over
all fractions. In this subsection, we will use the true, discretized probability distribution
for each of the patients, shown in Figure 3-2, to measure the best possible gain of using
an adaptive fraction size.
We run two simulations for each of the patients: 20% dose deviations from standard
fractionation and 50% dose deviations. For the 20% deviations, the range of possible
fraction sizes will lie within 20% of the standard 2 Gy per fraction, i.e. u = 1.6 Gy and
u = 2.4 Gy. For 50 % deviations, we have u = 1 Gy and u = 3 Gy. We use P = 76 Gy,
which results in 2 Gy per fraction for N = 38 days. We use the sum of the EUD (with
exponent a = 3) in the OAR over all fractions as a metric for comparison. Let DOARconv be
this EUD sum quantity when using the conventional 2 Gy per fraction and DOARadap when
using an adaptive fraction size. Using the true discretized probability distributions in
Figure 3-2, we find the resulting gain in total dose in the OAR when using an adaptive
fraction size (Table 3.3). Note that reduction in dose to the OAR is not more than 3%
for the three patients when using 50% deviations and around 1% or below when using
20% deviations. Note that patient 3 has the smallest gain which can be explained by the
little motion observed in the estimated dose ratio probability distribution in Figure 3-2.
These results indicate that using an adaptive fraction size is not much more beneficial
than standard fractionation, especially since we are measuring the best possible gain
assuming knowledge of the true probability distribution. Of course, larger deviations
in the fraction size would result in bigger gain, but ignoring biological effects by using
a physical dose model is not realistic. Indeed, it has been shown in [6] that biological
effects are insignificant only when dose variations are less than 10%.
84
Table 3.3: Adaptive fractionation for prostate cancer using physical dose model. In
this case, we note little gain when using adaptive fractionation. The dose to the OAR
for conventional and adaptive fractionation are denoted DOARconv and D
OAR
adap , respectively.
20% deviations 50% deviations
Patient DOARconv [Gy] D
OAR
adap [Gy] Gain [%] D
OAR
conv [Gy] D
OAR
adap [Gy] Gain [%]
1 51.52 50.96 1.09 51.52 50.11 2.74
2 54.53 54.02 0.92 54.53 53.26 2.33
3 47.65 47.46 0.40 47.65 47.16 1.03
3.4.3 Fractionation using BED model
We use the BED model and take into account the biological effect of varying the frac-
tion size. There can be considerable potential for significant gain especially because
we can allow for larger fraction size deviations. Now, we use rk+1 = f(rk, uk) = rk −
ukhk (1 + ukhk/[α/β]T ) for the dynamics equation and g(uk, hk) = ukhk (1 + ukhk/[α/β]O)
for the cost per fraction. We use typical α-β values for the tumor and OAR to compute
the BED. Prostate tumors are known to have a very small α-β ratio compared to other
disease sites [51]. This means that the tumor is sensitive to fractionation effects, and
thus, there is potential for significant gain when compared to standard fractionation
schemes. We use [α/β]T = 1.5 Gy and [α/β]O = 3 Gy. For standard fractionation, using
2 Gy per fraction for 38 fractions, we deliver a total BED of 38 · 2 (1 + 2/1.5) = 177.33
Gy to the tumor. Thus, we use this as the total prescription dose in BED to be delivered
to the tumor. The metric used for comparison to the standard fractionation scheme is
the sum of the BED in each fraction, estimated by the EUD in the OAR (with exponent
a = 3 as before). We denote this quantity D˜OARconv when using conventional fractiona-
tion and D˜OARadap when using adaptive fractionation. In comparison to the physical dose
model used in the previous subsection, we find a significant gain using the BED model,
especially when using 50% deviations from conventional fractionation (Table 3.4). We
note as much as 9% reduction in the BED in the OAR, which would be significant
enough to justify using adaptive fractionation. This type of improvement is probably
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Table 3.4: Adaptive fractionation for prostate cancer using BED model. We note
significant gain when using 50% deviations from standard fractionation. The BED in
the OAR are denoted D˜OARconv and D˜
OAR
adap for conventional and adaptive fractionation,
respectively.
20% deviations 50% deviations
Patient D˜OARconv [Gy] D˜
OAR
adap [Gy] Gain [%] D˜
OAR
conv [Gy] D˜
OAR
adap [Gy] Gain [%]
1 74.93 72.85 2.78 74.93 68.08 9.14
2 80.72 78.73 2.47 80.72 74.01 8.31
3 67.61 66.73 1.30 67.61 63.71 5.77
only going to arise for tumors with small α-β ratios like prostate cancer. Of course,
here we are using the true probability distribution to measure the best possible gain. In
a later subsection, we will investigate the result when using a probability distribution
different from the true one.
The linear-quadratic (LQ) model, from which it is possible to derive the BED model,
is an appropriate model for doses larger than 1 Gy [30] and doses smaller than 10 Gy [7].
It is thus possible for us to vary the dose more significantly than 20%. Clearly, this
would increase the benefit of adaptive fractionation, especially for tumors with small
α-β ratios like prostate cancer. We instead focus on an even more interesting type
of schedule, which we name adaptive hypofractionation. For tumors such as prostate
that have small α-β ratios, it is typical to hypofractionate (or deliver fewer number
of large fractions). In our case, given that we would like to deliver 5 fractions with a
total BED of 177.33 Gy as before, this results in delivering 6.58 Gy per fraction. In
principle, we could set the u = 1 Gy and u = 6.58 Gy and run our previous result.
However, we would like to address a more interesting question: can we deliver a few
large fractions adaptively over the course of treatment so that we can end the treatment
course earlier? We could use a principle similar to hypo-fractionation except that we
wait for the right opportunity to deliver the treatment. We propose an approximate
approach to solve this problem based on the previous algorithms. First, we solve the
fractionation problem with u = 0 Gy and u = 6.58 Gy. If the optimal dose is less than
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Table 3.5: Adaptive hypofractionation and standard hypofractionation in comparison
to conventional treatment. We show that there is a significant gain in BEDO for both
types of hypofractionated treatments. Adaptive hypofractionation does worse than
hypofractionation because the first five fractions were not unfavorable. If the first five
fractions were in fact unfavorable, adaptive hypofractionation may fair better than
simply hypofractionation.
Patient Adaptive hypofractionation [% gain] Hypofractionation [% gain]
1 14.63 24.51
2 13.31 25.99
3 21.26 26.54
2 Gy (e.g., 0 Gy), then deliver a 2 Gy fraction if possible or whatever remaining dose is
left to deliver. On the other hand, if the optimal dose is greater than 2 Gy (e.g., 6.58
Gy), then deliver the dose as is. Finally, if the remaining dose is 0 Gy midway during
the treatment course, the entire BED has been delivered and the patients treatment is
complete. We run this algorithm for the three prostate patient datasets and find that
adaptive hypofractionation does better than conventional fractionation (Table 3.5) and
takes advantage of the days in which the dose ratio is particularly small (Figure 3-3).
We also note in Figure 3-3 that the treatments are completed in 25 days for patients
1 and 2, and 18 days for patient 3, which are significantly fewer than the 38 fractions.
In Table 3.5, we have also simulated hypofractionated treatment by delivering 6.58
Gy for the first 5 fractions. While we note that hypofractionation does better than
adaptive hypofractionation, the gain can fluctuate significantly depending on the dose
ratios in the first 5 days. Thus, adaptive hypofractionation provides a balance between
conventional therapy and hypofractionated therapy; on the one hand, it addresses the
uncertainty of organ motion by waiting for the right opportunity and on the other,
provides a shorter, more effective treatment than conventional fractionation.
3.4.4 Updating probability distribution over treatment course
In this subsection, we analyze what happens when the prior probability distribution
estimated through historical data is very different from the true probability distribution.
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Figure 3-3: Illustration of adaptive hypofractionation for prostate patients. Note that
large fractions are delivered when the dose ratio is particularly small. We also note
fewer days of treatment delivery are required compared to conventional treatment.
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To investigate this, we construct a probability distribution that is different from the
ones in Figure 3-2. Consider a distribution which assigns 0.5 probability to the first two
buckets of the ten possible dose ratios in the interval [0.5, 1] (Figure 3-4). Using 50%
deviations from standard fractionation and the BED model with the same parameters
as in the previous subsection, we find that the gain reduces significantly (Table 3.6). To
address this problem, we use the algorithm suggested in Subsection 3.3.3. We update
the probability distribution over the course of treatment and re-run the DP algorithm
before the delivery of each fraction. We use a small concentration parameter cr = 2 to
put little weight on our prior distribution and a large weight on the observations from
the patient anatomy when updating the distribution. Figure 3-4 shows that about
midway through treatment (fraction 19), the probability distribution looks much closer
to the true one, and at the end of treatment, the probability distribution looks almost
identical to the true one. As treatment progresses, the time horizon over which the DP
algorithm is run gets smaller. In our simulation, we find the DP algorithm takes less
than 1.5 minutes for the first fraction and less than that for later fractions. We find
that this approach of updating the probability distribution achieves almost the entire
gain as when using the true distribution (Table 3.6). For patient 3, we find that this
algorithm does even better than when the true distribution is known. However, this
is only a single run; on average, the gain will be smaller when the true distribution is
known, regardless of whether it is being updated or not.
3.4.5 Treatment plan selection from a plan library
In this subsection, we quantify the benefit of adapting a plan both spatially (by se-
lecting from a plan library) and temporally (by adaptively varying the fraction size).
For the treatment plan selection, we choose the plan that results in the smallest dose
ratio as long as the target coverage is satisfied. In our example, we only have two
plans: CTV+2mm and CTV+5mm. The CTV+2mm plan has fewer target coverage
constraints, and thus, will have a smaller dose ratio than the CTV+5mm plan (assum-
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Figure 3-4: Illustration of probability distribution adapted over the course of treatment.
The top plot displays the prior probability distribution. The middle and bottom plots
show the updated distribution after the 19th and the last fraction. The concentration
parameter cr is chosen to be 2.
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Table 3.6: Improvement in gain when updating dose ratio probability distribution over
course of treatment. The BED model with 50% deviations is used. We quantify the
gain resulting from using the true probability distribution, resulting from using a prior
distribution significantly different from the true one, and resulting from using an up-
dated distribution. The gains are denoted Gtrue, Gprior, and Gupdated respectively. The
prior distribution assigns 0.5 probability to the first two buckets of the ten possible
dose ratios.
Patient Gtrue [%] Gprior [%] Gupdated [%]
1 9.14 5.95 8.94
2 8.31 4.92 7.76
3 5.77 2.95 6.39
ing we compute the dose ratio by dividing the EUD in the OAR by the target dose of 2
Gy). Our plan selection then reduces to whether or not the CTV+2mm plan provides
sufficient target coverage. If target coverage is ensured, the CTV+2mm is chosen, and
if not, the CTV+5mm is chosen. In order to determine target coverage, we compute
the EUD with exponent a = −20 in the CTV and make sure it is at least the required
dose of 2 Gy. If so, the CTV+2mm plan is delivered and otherwise the CTV+5mm
plan is delivered. We find significant reduction in the physical dose in the OAR re-
sulting from adaptively selecting these two types of plans (Table 3.7). We note that
the reduction in dose for patient 3 is much greater than the other two patients; this is
because the CTV+2mm plan was used for most (92.1%) of the fractions. This is quite
interesting because patient 3 received the least benefit compared to the others when
adaptively varying the fraction size. Indeed, the dose ratio probability distribution in
Figure 3-2 tells us that patient 3 had little organ motion. This leads us to conclude
that more organ motion is better for adaptive fractionation and little motion is better
for spatial adaptation. This is part of the reason why a combination of both spatial
adaptation and temporal dose variations can together result in significant improvement
in treatment effectiveness (Table 3.8).
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Table 3.7: Results from treatment plan selection. We compute the gain in the physical
dose to the OAR as a result of selecting between two plans. The conventional treatment
is to deliver the CTV+5mm plan throughout the treatment. The physical dose in the
OAR using conventional and adaptive selection are DOARconv and D
OAR
plan , respectively. The
fraction of the days that the CTV+2mm plan was used is given by Frac2mm.
Patient DOARconv [Gy] D
OAR
plan [Gy] Gain [%] Frac2mm [%]
1 51.52 45.90 10.90 55.3
2 54.53 53.99 0.99 18.4
3 47.65 38.48 19.24 92.1
Table 3.8: Results from using both adaptive fractionation and plan selection. The BED
model with 50% deviations was used. We note significant gain for all three patients.
The gain from using plan selection, from adaptive fractionation, and both are denoted
Gplan, Gadap, and Gboth respectively.
Patient D˜OARconv [Gy] Gplan Gadap [%] Gboth [%]
1 74.93 13.43 9.15 22.46
2 80.72 1.25 8.32 10.30
3 67.61 23.72 5.78 28.41
3.5 Discussion and conclusions
We have presented an adaptive spatio-temporal approach, which involves varying the
fraction size and selecting from a plan library. For the three prostate patients, we find
that adaptive fractionation based on a physical dose model does not result in significant
benefit. However, using the BED model, we find that there is significant gain, especially
because of the low α-β ratio of prostate cancer. We present an interesting concept called
adaptive hypofractionation, which is potentially beneficial. Further investigation of the
benefit of this approach would be useful. We show that an inaccurate estimate of the
dose ratio probability distribution can reduce the benefit considerably. But, updating
the distribution based on observations of the patient anatomy during the course of
treatment and using an approximate DP approach overcomes this problem. We find
that adaptive fractionation is beneficial when there is significant organ motion. On the
other hand, selection from a library of plans, which consist of differing margins around
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the tumor volume, is more beneficial when there is less motion. Thus, the combination
of both adaptive fractionation and treatment plan selection has a significant potential
for improving treatments.
We point out limitations and further remarks about our assumptions:
1. For the methods in this chapter, we required an image of the patient anatomy
before the delivery of every fraction. We hope that this information together with
reliable automatic contouring and/or contour registration algorithms [12] will be
available in the future.
2. We assumed that the dose ratio is computed fast enough before delivery of each
fraction. In this chapter, we re-computed the dose deposition matrix to determine
the OAR dose ratio. However, it is possible to approximate this by using the same
dose deposition matrix from the simulation CT for every fraction; this could be
reasonable for a photon beam modality. If possible, fast dose computation on a
CBCT image could also be used.
3. The patient setup in this chapter was assumed to be perfect. That is, for every
fraction, we aligned the center of mass of the target volume to be the isocenter. It
may be necessary to consider a margin of error here even with image guidance. We
do not consider other intangibles such as contouring error when ensuring target
coverage for the CTV. It may be necessary to add a slight margin to the CTV to
determine target coverage.
4. We used the dose to one primary OAR, the anterior rectum in the prostate case,
as a metric for treatment effectiveness. It is possible to use other appropriate
cost functions here. Using multiple OARs and tracking them separately could
be a useful direction for future research. This would, however, involve additional
states and would increase the computation time for the DP.
5. We did not compute DVH type metrics to determine treatment effectiveness. For
such metrics, it is necessary to use deformable registration tools to determine the
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total dose in each voxel. Perhaps such metrics can be used in the future given
these registration tools are more reliable.
Future work could include determining other disease sites that could benefit from
adaptive fractionation and/or plan selection from a library of plans. It is possible to
re-optimize a treatment plan before every fraction perhaps, but many treatment centers
require QA procedures. The pre-approved library of plans approach has the advantage
of not having to go through these extra QA procedures. In this chapter, we selected
a plan with a small margin and another with a large margin to be part of the plan
pool. However, this approach was heuristically determined from intuition. A question
of interest could be how one can generate such a plan library. It may be possible to
mathematically optimize, for example, two treatment plans to be part of the library
so that treatment effectiveness is maximized and target coverage is ensured. At first
glance, this problem appears to be combinatorial in nature and possibly difficult to
solve. This could be an interesting problem for future research.
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Chapter 4
Effect of tumor repopulation on
optimal fractionation
4.1 Introduction
Radiation therapy treatments are typically fractionated (i.e., spaced out in time) so
that normal tissue has time to recover. However, such time in between treatments
allows cancer cells to proliferate and can result in treatment failure [37]. The problem
of interest then is the determination of an optimal fractionation schedule to counter
the effects of tumor repopulation. In this chapter, we develop a framework for optimiz-
ing non-uniform (in time) dose schedules for general tumor growth curves, motivated
primarily by the phenomenon of accelerated repopulation, i.e., a faster repopulation of
surviving tumor cells towards the end of radiation treatment. Accelerated repopulation
is considered to be an important cause of treatment failure in radiation therapy, espe-
cially for head and neck tumors [91, 92]. We choose to model this behavior by using
decelerating tumor growth curves, where a larger number of tumor cells results in slower
growth. Thus, faster growth is exhibited towards the end of radiation treatment, when
there are fewer cells.
To determine an optimal fractionation schedule, we formulate an optimization prob-
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lem. Consider a tumor and one dose-limiting organ-at-risk (OAR). We assume that a
dose di to the tumor in the ith day results in a homogeneous dose of γdi to the OAR,
where γ is the normal tissue sparing factor that satisfies 0 < γ < 1. We would like to
maximize the tumor control probability (TCP) subject to an upper limit on the normal
tissue complication probability (NTCP). A convenient way to model TCP is to use
Poisson statistics [54], under which
TCP = exp(−X+N−1),
where X+N−1 is the expected number of tumor cells surviving after the last dose of
radiation. In this case, maximizing the TCP is equivalent to minimizing the expected
number of cells remaining at the end of treatment. For the rest of the chapter, we focus
on minimizingX+N−1 subject to a given level of probability of normal tissue complication.
In Section 4.2, we list the main contributions. In Section 4.3, we provide background
and existing results on optimal fractionation without tumor repopulation. In Section
4.4, we formulate the fractionation problem including general repopulation character-
istics. We propose a dynamic programming (DP) approach to solve the problem and
state the main result that optimal dose fractions are non-decreasing over time. In
Section 4.4.4, we analyze the special structure of the problem for the case of Gom-
pertz tumor growth. In Section 4.5, we discuss numerical results under exponential or
Gompertz growth models. The results indicate that accelerated repopulation suggests
larger dose fractions toward the end of treatment to compensate for the increased tumor
proliferation.
4.2 Contributions
In this chapter, we provide an insightful analysis of the effect of tumor repopulation on
optimal fractionation schemes. Specifically, we:
1. formulate a problem that includes general tumor repopulation characteristics and
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develop a DP approach to solve it.
2. prove that the optimal doses are non-decreasing over time, due to the decelerating
nature of tumor growth curves.
3. analyze the special structure of the problem for the case of Gompertz tumor
growth and show that it is equivalent to maximizing a discounted version of the
biological effective dose in the tumor.
4. show that when there is repopulation, the optimal number of dose fractions is
finite.
5. find through numerical simulations that faster tumor growth suggests shorter
overall treatment duration. In addition, the presence of accelerated repopula-
tion suggests larger dose fractions later in the treatment to compensate for the
increased tumor proliferation.
4.3 Optimal fractionation without tumor repopula-
tion
We provide some background relevant to optimal fractionation in the absence of repop-
ulation. This will be basis for the new results presented in Section 4.4. We first describe
the LQ model of radiation effects and the biological effective dose (BED) model. In the
second subsection, we state the optimal fractionation scheme when repopulation is not
considered [52].
4.3.1 LQ model
The relationship between radiation dose and the fraction of surviving cells is described
by the LQ model of radiation effects. Observations from irradiating cells in vitro support
this model [21]. The LQ model relates the expected survival fraction S after a single
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delivered dose d, in terms of two tissue parameters α and β, through the equation
S = exp(−(αd+ βd2)).
Thus, the logarithm of the survival fraction consists of a linear component with coeffi-
cient α and a quadratic component β (Figure 4-1). For N treatment days with radiation
doses d0, d1, . . . , dN−1, the resulting survival fractions from each individual dose can be
multiplied, assuming independence between dose effects. The resulting equation is
S = exp
(
−
N−1∑
k=0
(
αdk + βd
2
k
))
. (4.1)
The effect of the quadratic factor β, in the above equation, is that the survival fraction
is larger when splitting the total dose into individual dose fractions (Figure 4-1). Thus,
there is an inherent trade-off between delivering large single doses to maximize cell kill
in the tumor and fractionating doses to spare normal tissue. It is now clear that the
physical dose d by itself does not entirely capture the biological effect on tissue. A
common quantity that is used instead to quantify the effect of the radiation treatment
is the biological effective dose (BED). It is defined by
BED(d) =
1
α
(
αd+ βd2
)
= d
(
1 +
d
[α/β]
)
, (4.2)
where [α/β] is the ratio of the respective tissue parameters. Thus, the BED in the
above equation captures the effective biological dose in the same units as physical dose.
A small value [α/β] means that the tissue is sensitive to large doses; the BED in this
case grows rapidly with increasing dose. Note that BED, which is practically used to
quantify fractionation effects in a clinical setting, is related to the LQ model used in
vitro by setting BED = − ln(S)/α. With the relation given in Equation (4.2), we define
BEDT (d) as the BED in a tumor with parameter [α/β]T , and BEDO(d) as the BED in
an OAR with parameter [α/β]O. We assume throughout the chapter that [α/β]T and
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[α/β]O are positive. Finally, we also define (for convenience in notation) the total BED
in the tumor, BEDT , and the total BED in the OAR, BEDO, from delivering the doses
d0, d1, . . . , dN−1:
BEDT =
N−1∑
k=0
BEDT (dk) =
N−1∑
k=0
dk
(
1 +
dk
[α/β]T
)
and
BEDO =
N−1∑
k=0
BEDO(dk) =
N−1∑
k=0
γdk
(
1 +
γdk
[α/β]O
)
,
where γ is the sparing factor and [α/β]T and [α/β]O are the α/β-ratios in the tumor
and OAR, respectively. A common way to model normal tissue complication (NTCP) is
a sigmoidal function of the BED in the OAR, BEDO. Thus, since a sigmoidal function
is monotonic in its argument, it suffices to impose an upper limit on BEDO. From here
on, our optimization problem of interest is to minimize the expected number of tumor
cells subject to an upper limit on BEDO. The problem is stated mathematically as
minimize
{di≥0}
X+N−1 s.t. BEDO ≤ c, (4.3)
where X+N−1 is the expected number of tumor cells after radiation treatment and c is
an appropriate constant.
4.3.2 Optimal BED based fractionation
In the absence of repopulation, the expected number of cells at the end of treatment,
X+N−1, is X0S, where X0 is the initial number of tumor cells and S is the expected
survival fraction given in (4.1) resulting from delivering doses d0, d1, . . . , dN−1. Taking
natural logarithms and dividing by −αT , where αT is a tumor tissue parameter, mini-
mizing the expected number of tumor cells is equivalent to maximizing the BED in the
tumor, BEDT . The next lemma states that the constraint on BEDO is always binding.
Lemma 4.3.1. In the absence of repopulation, the constraint in (4.3) will be satisfied
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Figure 4-1: Illustration of the fractionation effect using the LQ model. The cell kill
is exponential with both a linear and a quadratic term. Fractionating into multiple
individual doses results in a much lower survival fraction compared to a single dose
assuming the quadratic β term is significant.
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with equality at the optimum.
Proof. See Appendix 4.8.1.
Thus, a simplified version of the optimization problem without repopulation is
maximize
{di≥0}
BEDT s.t. BEDO = c. (4.4)
We characterize the set of all optimal solutions to this problem in the following theorem,
published in [52].
Theorem 4.3.2. Let N be given. If [α/β]O ≥ γ[α/β]T , an optimal solution is to deliver
a single dose equal to
d∗j =
[α/β]O
2γ
[√
1 +
4c
[α/β]O
− 1
]
(4.5)
at an arbitrary time j and deliver di = 0 for all i 6= j. This corresponds to a hypo-
fractionation regimen, i.e., a fractionation schedule that uses as few treatment days as
possible. If [α/β]O < γ[α/β]T , the unique optimal solution consists of uniform doses
given by
d∗j =
[α/β]O
2γ
[√
1 +
4c
N [α/β]O
− 1
]
, (4.6)
for j = 1, 2, . . . , N . This corresponds to a hyper-fractionation regimen, i.e., a fraction-
ation schedule that uses as many treatment days as possible.
Proof. A geometric proof is given in [52]. An alternate proof is provided in Appendix
4.8.2.
The above theorem states that if [α/β]O is small enough, i.e., the OAR is sensitive to
large doses and [α/β]O < γ[α/β]T , it is optimal to deliver the same dose during the N
days of treatment. Besides the distribution of doses during treatment for a fixed value
of N , the above theorem also has an interpretation on the optimal number of treatment
days, N∗. Note that taking N larger will only improve the objective BEDT and add
extra degrees of freedom. If [α/β]O ≥ γ[α/β]T , the theorem states that a single radiation
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dose is optimal, i.e., N∗ = 1. On the other hand, if [α/β]O < γ[α/β]T , the optimal
solution consists of uniform doses with N as large as possible. This would correspond to
choosing N∗ →∞. For most disease sites, the condition [α/β]O < γ[α/β]T is generally
satisfied. Clearly, N∗ →∞ is not realistic and is an artifact of modeling assumptions.
Later in the chapter, we will show how modeling tumor repopulation results in a finite
optimal number of treatment days.
4.4 Optimal fractionation for general tumor repop-
ulation
In this section, we present the problem statement and a solution method that determines
an optimal fractionation schedule for the case of general tumor growth.
4.4.1 Problem formulation
We are interested in minimizing the expected number of tumor cells at the end of
treatment. The two aspects that determine the expected number of cells at any point in
time are the sequence of doses that are delivered and the dynamics of the tumor growth
in between doses. Let us denote by x(t) the expected number of tumor cells at time t,
for any t between 0 and N − 1. We assume the sequence of N doses d0, d1, . . . , dN−1
are delivered at integer times, i.e., time is measured in days. For these integer times
i = 0, 1, . . . , N −1, the effect of radiation doses is described by the LQ model, resulting
in
x(i+) = x(i−) exp(−(αTdi + βTd2i )), (4.7)
where i− and i+ are the times immediately before and after delivering the dose di. The
dynamics of x(t) modeling tumor growth for non-integer times in [0, N−1] is described
by the differential equation
1
x(t)
dx(t)
dt
= φ(x(t)), (4.8)
102
with the initial condition x(0) = X0 for the initial number of cells. In the above
equation, φ(x) represents an instantaneous tumor proliferation rate. By choosing an
appropriate functional form of φ, we can describe a variety of tumor repopulation
characteristics relevant for radiation therapy:
1. By choosing φ(x) = ρ, we model exponential tumor growth with a constant
proliferation rate ρ.
2. By choosing φ(x) to be a decreasing function of x, we are able to mimic the
case of accelerated repopulation [91, 92]. In this case, the instantaneous tumor
proliferation rate increases when, towards the end of treatment, the number of
remaining tumor cells decreases.
In the remainder of this section, we first consider the optimal fractionation problem for
a general proliferation rate φ(x). In Section 4.4.2, a DP approach is proposed to solve
the problem. In Section 4.4.3, the property that the optimal doses are non-decreasing
over time is established. In Sections 4.4.4 and 4.4.5, we consider the special cases of
Gompertzian growth (as a model for accelerated repopulation) and exponential growth
(as a model of constant repopulation), respectively.
We define some additional notation for ease of exposition. Since the range of possible
values of x(t) is large and the cell kill factor is exponential according to the LQ model,
it is convenient to work with the logarithm of x(t). Hence, we define y(t) = ln(x(t))/αT .
We also define X−i = x(i
−) and X+i = x(i
+) to be the expected number of tumor cells
remaining immediately before and after delivering the dose di, respectively. Similarly,
the logarithmic counterparts are Y −i = ln(X
−
i )/αT and Y
+
i = ln(X
+
i )/αT . We will
assume that the initial number of cells are X0 = X
−
0 , and Y0 = Y
−
0 for the logarithmic
version. Note that the equivalent of Equation (4.7) for y(t) is
Y +i = Y
−
i − BEDT (di),
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Figure 4-2: Schematic illustration of the expected number of tumor cells over the course
of treatment. The effect of radiation dose d is a reduction in the log of the number of
cells, proportional to BEDT (d).
where BEDT (di) is defined as before. We also define a growth function F that maps
Y + to Y − using the appropriate differential equation equivalent of (4.8). Thus, Y −i+1 =
F (Y +i ) for i = 0, 1, . . . , N −1. Figure 4-2 provides an illustration of the behavior of the
expected number of tumor cells over the course of treatment.
4.4.2 Dynamic programming approach
The optimization problem of interest is to minimize the expected number of tumor cells
at the end of treatment, X+N−1, under the constraint that the BED in the OAR, BEDO,
is less than or equal to some constant c. Equivalently, we choose to minimize Y +N−1. In
order to get from the initial Y0 to Y
+
N−1, one recursively alternates between applying a
dose d and the growth function F . That is, Y +N−1 takes the form
Y +N−1 = F (· · ·F (F (Y0 − BEDT (d0))− BED(d1)) · · · )− BED(dN−1). (4.9)
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Such a recursive formulation lends itself naturally to a DP approach to solve the prob-
lem. We can solve the formulation by recursively computing an optimal dose backwards
in time. Note that although non-linear programming methods can be used, there is no
guarantee of the convexity of the objective (4.9), and the solution might provide only a
local optimum. On the other hand, a global optimum is guaranteed if the DP approach
is used.
We now formulate the problem in a DP framework. We define zi to be the cumula-
tive BED in the OAR resulting from delivering the doses d0, d1, . . . , di−1. We wish to
determine the dose di based on Y
+
i−1 and the cumulative BED in the OAR zi. Here, Y
+
i−1
and zi together represent the state of the system because they are the only relevant
pieces of information needed to determine the dose di. Instead of additive costs, we
choose to formulate the problem by including only a terminal cost. Specifically, we
include the final expected (logarithmic) number of cells Y +N−1 in the terminal condi-
tion. In order to ensure that the BEDO constraint is satisfied, we also assign an infinite
penalty to the terminal cost when the constraint is violated. The Bellman recursion to
solve the problem is:
JN(Y
+
N−1, zN) =
 Y
+
N−1, if zN ≤ c,
∞, otherwise,
Jk(Y
+
k−1, zk) = min
dk≥0
[
Jk+1(F (Y
+
k−1)− BEDT (dk))
]
,
for k = N − 1, N − 2, . . . , 1. The initial equation for time 0, given below, is slightly
different because there is no prior tumor growth
J0(Y
−
0 , z0) = min
d0≥0
J1(Y
−
0 − BEDT (d0)).
For numerical implementation, the above state variables need to be discretized and the
tabulated values stored. For evaluating the cost-to-go function Jk at any non-discretized
values, an interpolation of appropriate discretized values can be used for accuracy.
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4.4.3 Properties of the optimal fractionation scheme
We begin with two lemmas. The first one is simply a counterpart of Lemma 4.3.1 for
the case where there is tumor repopulation.
Lemma 4.4.1. Assume that φ(x) > 0 for all x > 0. For the fractionation problem that
includes tumor repopulation, the constraint on BEDO will be satisfied with equality.
Proof. See Appendix 4.8.3.
Lemma 4.4.2. Assume that φ(x) > 0 for all x > 0. Suppose that i < j and that we
apply the sequence of doses di+1, . . . , dj starting with either Y
+
i or Y˜
+
i . If Y
+
i < Y˜
+
i ,
then Y +j < Y˜
+
j .
Proof. See Appendix 4.8.4.
The second lemma above provides a monotonicity property of the mapping of the
expected number of cells from point in time to another, assuming that the same sequence
of doses are applied. Next, we state the following theorem.
Theorem 4.4.3. Let us fix N . Assume that the instantaneous tumor growth rate φ(x)
is non-increasing as a function of the number of cells x, and that there is always some
amount of repopulation, i.e., φ(x) > 0 for all x > 0. If [α/β]O ≥ γ[α/β]T , the optimal
solution is to deliver a single dose as in Theorem 4.3.2. If [α/β]O < γ[α/β]T , then the
optimal doses must increase over the course of treatment. That is, the optimal doses
will satisfy d∗0 ≤ d∗1 ≤ · · · ≤ d∗N−1.
Proof. See Appendix 4.8.5.
For the case where [α/β]O ≥ γ[α/β]T , it is reasonable that the optimal solution is to
use the most aggressive treatment of a single dose with the optimal N∗ = 1 because
this is the case even without repopulation. The interesting case is that when [α/β]O <
γ[α/β]T , the doses must increase over time. Intuitively, due to the decreasing property
of φ(x) as a function of x, the tumor grows at a faster rate when its size becomes smaller
over the course of treatment; higher doses are then required to counter the increased
proliferation.
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4.4.4 Gompertzian tumor growth
In this subsection, we discuss the Gompertz tumor growth model and present a sim-
plified DP approach with a reduced state space. The Gompertz equation a particular
model of a decelerating tumor growth curve. The dynamics are described by a differ-
ential equation that has the instantaneous proliferation rate
φ(x) = b ln
(
X∞
x
)
,
where X∞ is the carrying capacity and b is a parameter that controls the rate of growth.
(Here, the asymptotic limit X∞ is more of a mathematical abstraction rather than a
meaningful physical quantity; the death of a host would occur long before there are
X∞ tumor cells.) The resulting analytical solution n(t) from solving the differential
equation (4.8) with initial condition n(0) = X0 is
n(t) = X∞ exp
[
ln
(
X0
X∞
)
exp(−bt)
]
= X
exp(−bt)
0 X
1−exp(−bt)
∞ , (4.10)
Here, n(t) is used to denote the expected number of tumor cells without radiation
treatment; this is to avoid confusion with the already defined x(t). The above equation
models slower repopulation for larger tumor sizes and vice-versa (see Figure 4-3).
For the case of Gompertzian tumor growth, it turns out that one can significantly
simplify the problem and solution approach. We will now derive an explicit expression
for the expected number of tumor cells at the end of treatment. We claim that
Y +i =
1
αT
ln (n(i))−
i∑
k=0
exp[−b(i− k)]BEDT (dk), (4.11)
for i = 0, 1, . . . , N−1, where n(t) represents the expected number of tumor cells without
any radiation treatment. The above equation (4.11) holds for i = 0 because n(0) = X0
and Y +0 = ln(X0)/αT −BEDT (d0). For the inductive step, suppose the equation (4.11)
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Figure 4-3: Various types of tumor growth curves. The Gompertz and logistic equations
both model slower growth for larger number of cells. The exponential model assumes
a constant growth rate.
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holds true. From the Gompertz growth equation (4.10), assuming the time interval
between fractions is one day (implying t = 1), we can write the function F mapping
Y +i to Y
−
i+1 resulting from tumor growth as
Y +i+1 = F (Y
+
i ) = exp(−b)Y +i + (1− exp(b))
ln(X∞)
αT
.
Incorporating the growth and the radiation dose from di+1, we find
Y +i+1 = F (Y
+
i )− BEDT (di+1)
=
1
αT
ln
(
n(i)exp(−b)X(1−exp(b))∞
)− i+1∑
k=0
exp[−b(i+ 1− k)]BEDT (dk)
=
1
αT
ln (n(i+ 1))−
i+1∑
k=0
exp[−b(i + 1− k)]BEDT (dk),
completing the inductive step. This results in the optimization problem
minimize
{di≥0}
1
αT
ln (n(N − 1))−
N−1∑
k=0
exp[−b(N − 1− k)]BEDT (dk)
s. t. BEDO ≤ c,
(4.12)
Notice the similarity between the problem without repopulation (4.4) and the above
problem (4.12) that includes Gompertzian tumor growth. The only addition is the ex-
ponential weighting term in the objective and the additive term. Note that the additive
term ln (n(N − 1)) /αT has no impact on the optimization because it is independent of
the dose fractions dk. However, if we were also to optimize over the number of fractions,
N , this term would come into play. Because the weighting term gives larger weight to
later fractions, we can conjecture that the optimal fractionation scheme will result in
larger fraction sizes towards the end of treatment.
From (4.12), we see that the expected number of tumor cells is not required as
a state variable; we can thus simplify the DP equation. We also choose to include
additive costs as opposed to a terminal cost as was done for the general case. The
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updated algorithm is
JN(zN ) =
 0, if zN = c,∞, otherwise,
Jk(zk) = min
dk≥0
[
exp[−b(N − 1− k)]BEDT (dk) + Jk+1(zk + BEDO(dk))
]
, (4.13)
for k = N − 1, N − 2, . . . , 0. For numerical implementation, we discretize the state
variable zk and solve a corresponding discrete problem. For evaluating the above J
function for general values of z, linear interpolation was used.
4.4.5 Exponential tumor growth with constant repopulation
rate
In this subsection, we discuss the exponential tumor growth model for which we provide
the optimal fractionation scheme in closed form. As opposed to Gompertzian growth,
the rate of growth does not change with tumor size (see Figure 4-3), and there is no
upper limit (i.e., X∞) on the number of tumor cells. The growth equation in this case
is
n(t) = X0 exp(ρt),
where X0 is the initial number of cells, as before, and ρ > 0 is the proliferation rate.
This corresponds to the case where φ(x) is constant and equal to ρ. We will show that
for exponential growth, the solution can be described in closed form.
Assuming ρ represents a measure of growth per unit day (or fraction), the number
of tumor cells is multiplied by a factor of exp(ρ) after every fraction. Since there are
N dose fractions and N − 1 days of repopulation in between treatment, the resulting
survival fraction of cells ST is
ST = exp (−αTBEDT + (N − 1)ρ) .
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By taking the logarithm, we obtain the following optimization problem:
maximize
{di≥0}
BEDT − 1
αT
(N − 1)ρ s.t. BEDO = c. (4.14)
This is the same problem as the one for the case without repopulation, except for the
additional − 1
αT
(N − 1)ρ term. For a fixed N , this additional term does not change
when varying the set of doses {di}. Thus, the optimal doses under the case of constant
exponential growth is exactly the same as in Theorem 4.3.2 for a fixed N .
To determine the optimal number of fractions N∗, one could compute the objective
(4.14) by brute force for a range of reasonable values of N . However, for the exponential
tumor growth case, one can characterize the optimal number of fractions in closed form.
The result is consistent and similar to the work in [2, 32, 89] though it is interpreted
differently here.
Theorem 4.4.4. The optimal number of fractions N∗ for exponential growth with con-
stant repopulation rate ρ is obtained by following this procedure:
1. If [α/β]O ≥ γ[α/β]T , then N∗ = 1.
2. If [α/β]O < γ[α/β]T , then
(a) Compute Nc = A
(√
(ρ+B)2
ρ(ρ+2B)
− 1
)
, where A = 2c2
[α/β]O
, B = αT [α/β]O
2γ
(
1− [α/β]O
γ[α/β]T
)
.
(b) If Nc < 1, then N
∗ = 1. Otherwise, evaluate the objective at ⌊Nc⌋ and ⌈Nc⌉,
and let the optimum N∗ be the one that results in a larger objective value.
Proof. See Appendix 4.8.6.
This result also makes sense in the limiting cases when ρ → 0 and ρ → ∞. When
approaching the case of no repopulation, i.e., ρ → 0, we see that Nc → ∞ and the
optimum N approaches infinity. When ρ → ∞, we see that Nc → 0, meaning that
the optimum N is a single dose when repopulation becomes very large. Recall that if
[α/β]O < γ[α/β]T , the optimal N approaches infinity for the case without repopulation.
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For the case of exponential repopulation with constant rate, the above result shows that
the optimum N is finite. Indeed, even for general tumor growth characteristics, as long
as there is repopulation, the optimal number of fractions is finite. The result is stated
in the following theorem.
Theorem 4.4.5. Suppose that there exists r > 0 such that φ(x) > r for all x > 0.
Then, the optimal number of fractions N∗ is finite.
Proof. See Appendix 4.8.7.
4.5 Numerical experiments
4.5.1 Faster tumor growth suggests shorter treatment dura-
tion
We use realistic choices of radiobiological parameters in order to simulate the effect
of various rates of tumor growth on the optimal number of treatment days. Here, we
assume exponential growth with a constant rate of repopulation. We use [α/β]T = 10
Gy, [α/β]O = 3 Gy, and αT = 0.3 Gy
−1 for the tissue parameters; these are appropriate
standard values [27]. We consider a standard fractionated treatment as reference, i.e.,
a dose of 60 Gy delivered to the tumor in 30 fractions of 2 Gy. For the above choice
of α/β-ratios and γ = 0.7, this corresponds to an OAR BED of 61.6 Gy, which we use
as the normal tissue BED constraint c. In order to choose appropriate values for the
proliferation rate ρ, we relate it to the tumor doubling time τd. Since τd represents the
time it takes for the tumor to double in size, we set exp(ρt) = 2t/τd , resulting in the
following relation:
ρ =
ln(2)
τd
.
For human tumors, the doubling time can range from a few days to a few months,
depending on the particular disease site. We show that for the parameters used above,
the optimal number of treatment days is smaller for faster growing tumors (Figure 4-4).
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The objective value plotted in Figure 4-4 is given by
BEDT − 1
αT
(N − 1)ρ.
For the reference treatment (N = 30) and α = 0.3, the decrease in the tumor BED due
to the second term (N − 1)ρ/αT evaluates to about 1.3 Gy for a slowly proliferating
tumor with doubling time τd = 50. This is small compared to BEDT = 72. For a fast
proliferating tumor with doubling time τd = 5, the correction (N−1)ρ/αT is about 13.4
Gy and becomes more important. Thus, smaller values of N are suggested for faster
proliferating tumors.
4.5.2 Accelerated repopulation suggests increasing doses to-
wards the end of treatment
One way to model accelerating repopulation is to use decelerating tumor growth curves
(see Figure 4-3). We model this behavior by using the Gompertz tumor growth model
and solve the fractionation problem by using the simplified DP equation (4.13). We
illustrate optimal fractionation schemes for both slow and fast proliferating tumors. For
a slow proliferating tumor, we choose the parameters X0 = 8.3×106, X∞ = 3×1012, and
b = exp(−6.8) so that the doubling time corresponding to the instantaneous growth
rate φ(x) starts at 50 days in the beginning of treatment and decreases to 20 days
at the end of treatment. For a fast proliferating tumor, we adjust the parameters
accordingly so that the doubling time goes from 50 days to 5 days: X0 = 3.6 × 1011,
X∞ = 3 × 1012, and b = exp(−5). As before, we use the parameters [α/β]T = 10
Gy, [α/β]O = 3 Gy, αT = 0.3 Gy
−1, c = 61.6 Gy, and γ = 0.7. As shown in Figure
4-5, for a fast proliferating tumor, the sequence of radiation doses increase from 1 Gy
to 3 Gy, which is a significant difference from the standard treatment of 2 Gy per
day for 30 days. For a slowly proliferating tumor, the doses closely resemble standard
treatment and only increase slightly over the course of treatment. Note that the dose
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Figure 4-4: Optimal number of fractions assuming exponential tumor growth. The
optimal number of treatment days is smaller for faster growing tumors. The expression
in Theorem 4.4.4 was used to generate this plot. In order to obtain the actual optimum
N , the objective must be evaluated at the floor and ceil of the continuous optimum N
plotted above.
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per day is almost exactly proportional to the plotted instantaneous proliferation rate
φ(x). In summary, we find that the optimal fractionation scheme distributes the doses
so that they are proportional to the instantaneous proliferation rate. For the reference
treatment of 2 per day with N = 30, in the case of a fast proliferating tumor, the
objective Y +N−1 is 24.25. The objective Y
+
N−1 for the optimal fractionation scheme in
plot b) of Figure 4-5 is 23.64. This is only a change of 2.5% in Y +N−1 and about 16.7%
change in X+N−1 in comparison to the reference treatment. It is not straightforward to
make a meaningful statement about the improvement in tumor control simply based
on these values. However, we can say that even a small improvement in tumor control
for a specific disease site can make a significant impact because of the large of patients
treated with radiation therapy every year.
4.5.3 Smaller α-β ratio of tumor results in larger changes in
fraction size and more gain
We use a smaller value for the α-β ratio of tumor and re-run the calculations from the
previous subsection. The parameters of the Gompertzian growth remain the same for
the slow and fast proliferating tumor. As before, we use the parameters [α/β]O = 3
Gy, αT = 0.3 Gy
−1, c = 61.6 Gy, and γ = 0.7, with the only change being [α/β]T = 5.7
Gy. Note that the condition [α/β]O = 3 < γ[α/β]T = 4 is satisfied, meaning that
delivering only a single dose of radiation is not optimal (see Theorem 4.4.3). As seen
in Figure 4-6, we find that for a fast proliferating tumor, the sequence of radiation
doses increase all the way to 5 Gy, which is an even more significant difference from the
results in the previous section. Indeed, in this case, the objective Y +N−1 is 16.00 for the
reference treatment of 2 Gy per day, and is 14.01 for the optimal fractionation scheme
in plot b) of Figure 4-6. This is a significant change of 12.4% in Y +N−1 and about 44.5%
change in X+N−1 in comparison to the reference treatment. Due to the change in the
optimal fractionation scheme, the rates of tumor growth have also changed. However,
these tumor growth rate changes have not been significant: the tumor doubling time
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Figure 4-5: Optimal fractionation for accelerated repopulation. Plot a) is an example
of a slow proliferating tumor, and plot b) is an example of a fast one. The doubling
time for the proliferation rate φ(x) begins at τd = 50 days and decreases to a) 20 and
b) 5 days, respectively, at the end of treatment. Larger dose fractions are suggested
later in the treatment to compensate for the increased tumor proliferation.
116
at the end of treatment is about 18 days for the slowly proliferating tumor and 4 days
for the fast one. The exponential increase of the optimal fractions observed plot b) of
Figure 4-6 is likely due to the assumed Gompertzian tumor growth characteristic. The
take away message should not be that the dose increases have an exponential nature,
but rather that the fractions are proportional to the instantaneous proliferation rate.
Should it be that the proliferation rate increases linearly, the result would likely be
linearly increasing dose fractions. We can infer that a smaller α-β ratio of the tumor
suggests using larger changes in fraction size; this results in larger gains in the objective
value and hence in overall tumor control. Low values of the α-β ratio have been observed
for disease sites such as prostate cancer [51]. Of course, if the α-β ratio is very small,
a single dose would be optimal (see Theorem 4.4.3).
4.6 Further remarks
4.6.1 Non-uniform irradiation of the OAR
Although we assumed throughout the chapter that a dose d results in a homogeneous
dose γd to the OAR, in reality the OAR receives a non-uniform irradiation. In [78], the
basic result stated in Theorem 4.3.2 is generalized to arbitrary inhomogeneous doses
in the OAR. The arguments in [78] are also applicable to the case of repopulation
as considered here. In this case, we can define an effective sparing factor γeff and an
effective upper limit ceff on the BEDO. The results differ for the case of parallel OAR
and serial OAR. A parallel organ could remain functional even with damaged parts;
a serial OAR on the other hand remains functional only when all of its parts remain
functional. For the case of a parallel OAR (e.g., lung), assuming γid represents the dose
in the ith voxel (or spatial point) in the OAR, the integral BED in the OAR is given
by
BEDO =
N−1∑
k=0
∑
i
γi dk
(
1 +
γi dk
[α/β]O
)
.
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Figure 4-6: Optimal fractionation for accelerated repopulation in the case of [α/β]T =
5.7 Gy. Plot a) is an example of a slowly proliferating tumor, and plot b) is an example
of a fast one. The doubling time for the proliferation rate φ(x) begins at τd = 50 days
and decreases to a) 18 and b) 4 days, respectively, at the end of treatment. Smaller
[α/β]T values result in larger changes in fraction size and more gain.
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By algebraic manipulations, we obtain the same form for the normal tissue constraint
as discussed in this chapter:
N−1∑
k=0
γeff dk
(
1 +
γeff dk
[α/β]O
)
= ceff,
where γeff =
∑
i γ
2
i /
∑
i γi and ceff = cγeff/
∑
i γi. For the serial case (e.g., spinal cord),
only the maximum dose to the OAR matters, resulting in γeff = maxi γi and ceff = c.
Further details can be found in [78].
4.6.2 Variable time intervals
The above methodology is applicable also for the case of variable time intervals (e.g.,
weekends, holidays). However, in our formulation we neglect the Lea-Catcheside factor,
i.e., we assume that each radiation treatment is delivered in a short time period, and
time between fractions is long. Without these assumptions, the survival fraction will
have to take into account biological aspects such as incomplete sublethal damage. The
LQ model used in our formulation does not take such factors into account. For optimal
fractionation schemes resulting from incorporating incomplete sublethal damage repair,
see [5].
4.6.3 Multiple OARs
When optimizing the spatial dose distribution, radiation treatments generally involves
making tradeoffs in dose delivered to multiple OARs. In this work, we assume that
the spatial dose distribution is fixed, and that the fractionation schedule is temporally
optimized. Even with multiple OARs, a single OAR will be dose-limiting, which pri-
marily determines the optimal fractionation schedule. Thus, this OAR can be used for
the BEDO constraint discussed in this chapter.
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4.7 Discussion and conclusions
There are multiple ways to model accelerated repopulation. One approach is to increase
the tumor proliferation rate with already delivered dose or BED. In this chapter, we
chose to model accelerated repopulation implicitly by using a decelerating tumor growth
curve, e.g., Gompertzian growth, with a proliferation rate φ(x) that is dependent on
the number of tumor cells. Due to radiation treatment, fewer cells remain towards the
end of treatment resulting in faster tumor growth. We developed a DP framework to
solve the optimal fractionation problem with repopulation for general tumor growth
characteristics described by φ(x). More research is needed to determine φ(x) from
clinical outcome data for a specific disease site. We derived the special structure of the
problem when assuming Gompertzian tumor growth. This resulted in maximizing a
discounted version of BEDT , which placed a higher weight for later treatment days due
to increased tumor proliferation.
There are three main messages in this chapter. First, faster tumor growth suggests
shorter overall treatment duration. Second, accelerated repopulation suggests larger
dose fractions later in the treatment to compensate for the increased tumor proliferation.
And, finally, the optimal fractionation scheme uses more aggressive changes in the dose
fractions when the α-β ratio of the tumor is smaller; in this case, we can expect larger
gains in tumor control.
The advantage of the methods presented in this chapter is that a change in the
fractionation schedule can be readily implementable in a clinical setting, without tech-
nological barriers. However, the results presented in this chapter are for illustrative
purposes and should not be taken as immediate recommendations for a change in clin-
ical practice. We realize that actual tumor dynamics are more complex than presented
in this chapter. Yet, we hope that this analysis can provide useful insights and a basis
for further research.
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4.8 Appendix: proofs
4.8.1 Proof of Lemma 4.3.1
Proof. Suppose an optimal solution is d∗i , for i = 0, 1, . . . , N − 1, but the constraint in
(4.3) is not active. That is, there exists δ > 0 such that
N−1∑
k=0
γd∗k
(
1 +
γd∗k
[α/β]O
)
+ δ = c.
For every fraction i, let us increase d∗i by the same positive constant ǫ. Choosing ǫ small
enough so that
∑N−1
k=0 γǫ
(
1 + γ
[α/β]O
(2d∗k + ǫ)
)
< δ, we see that
N−1∑
k=0
γ(d∗k + ǫ)
(
1 +
γ(d∗k + ǫ)
[α/β]O
)
=
N−1∑
k=0
γd∗k
(
1 +
γd∗k
[α/β]O
)
+
N−1∑
k=0
γǫ
(
1 +
γ
[α/β]O
(2d∗k + ǫ)
)
<
N−1∑
k=0
γd∗k
(
1 +
γd∗k
[α/β]O
)
+ δ
= c,
which means that the constraint in (4.3) is satisfied. Furthermore, choosing d∗i + ǫ,
for i = 0, 1, . . . , N − 1, results in a strictly larger objective value than that of the
supposed optimal solution. This is a contradiction because we have found a strictly
better solution than the assumed optimal one.
4.8.2 Proof of Theorem 4.3.2
Proof. Using the equality constraint in (4.4), we can equivalently write the objective
BEDT as
BEDT =
(
1− [α/β]O
γ[α/β]T
)N−1∑
k=0
dk +
[α/β]O
γ[α/β]T
c.
Thus, if [α/β]O ≥ γ[α/β]T , we would like to minimize
∑N−1
k=0 dk subject to a fixed
BEDO. Otherwise, if [α/β]O < γ[α/β]T , we would like to maximize
∑N−1
k=0 dk. First,
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let us assume the former condition [α/β]O ≥ γ[α/β]T to be true. Suppose an optimal
solution is to deliver a non-zero dose in more than one fraction, i.e., that there exists i
and j with i 6= j such that d∗i > 0 and d∗j > 0. We would like to show that, leaving dk
unchanged for k 6= i, j, a better solution is to set di equal to 0 and dj equal to the dose
that would satisfy the constraint in (4.4). Essentially, this would mean that there is no
reason to “spread out” the dose among the fractions; it would be optimal to deliver all
the dose in a single fraction. We now set di = 0 and dj = d
∗
j + δ, where δ is positive
constant appropriately chosen so that the constraint in (4.4) is satisfied. Writing out
the constraint equation and carrying out algebra, we find
N−1∑
k=0
γdk
(
1 +
γdk
[α/β]O
)
=
∑
k 6=i
k 6=j
γd∗k
(
1 +
γd∗k
[α/β]O
)
+ γ(d∗j + δ)
(
1 +
γ(d∗j + δ)
[α/β]O
)
= c+ f1(d
∗
i , d
∗
j , δ),
where for the last equality we used the fact that the assumed optimal solution satisfies
the constraint in (4.4). The function f1 is defined as
f1(d
∗
i , d
∗
j , δ) = γδ
(
1 +
γδ
[α/β]O
)
− γd∗i
(
1 +
γd∗i
[α/β]O
)
+
2γ2δd∗j
[α/β]O
. (4.15)
Thus, we can choose δ > 0 that satisfies f(d∗i , d
∗
j , δ) = 0 to ensure the constraint in
(4.4). Since the third term in (4.15) is positive, such a choice of δ will result in δ < d∗i .
However, this means that we have found a strictly better solution because
N−1∑
k=0
dk =
∑
k 6=i
d∗k + δ <
N−1∑
k=0
d∗k,
resulting in a contradiction of the optimality assumption. Therefore, for [α/β]O ≥
γ[α/β]T , an optimal solution has exactly one non-zero dose. The closed-form solu-
tion, as given in (4.5), can be obtained by solving the quadratic equality constraint
γdj
(
1 +
γdj
[α/β]O
)
= c.
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Now, assume that [α/β]O < γ[α/β]T , and suppose that there exists i and j with
i 6= j such that d∗i 6= d∗j , with both d∗i and d∗j non-zero. We would like to show that,
leaving unchanged dose fractions at times other than i or j, a better solution is to
deliver equal dose in fractions i and j, scaled appropriately so that the constraint in
(4.4) is satisfied. Essentially, this would mean that the optimal solution “spreads out”
the dose uniformly amongst all fractions. Hence, we set di = dj = δ(d
∗
i + d
∗
j)/2, with
an appropriately chosen positive constant δ. Writing out the constraint equation and
carrying out the algebra, we find
N−1∑
k=0
γdk
(
1 +
γdk
[α/β]O
)
=
∑
k 6=i,j
γd∗k
(
1 +
γd∗k
[α/β]O
)
+ 2γδ
d∗i + d
∗
j
2
(
1 +
γδ
[α/β]O
d∗i + d
∗
j
2
)
=
∑
k 6=i,j
γd∗k
(
1 +
γd∗k
[α/β]O
)
+ f2(d
∗
i , d
∗
j , δ), (4.16)
where
f2(d
∗
i , d
∗
j , δ) = δγd
∗
i
(
1 +
δγd∗i
[α/β]O
)
+ δγd∗j
(
1 +
δγd∗j
[α/β]O
)
− (γδ)
2
2[α/β]O
(d∗i − d∗j)2.
Note that if we choose δ = 1, Equation (4.16) would simplify to c minus the third term
in the definition of the function f2. Clearly, in order to ensure that the expression in
(4.16) equals c and thus satisfies the BEDO equality constraint, δ > 1 must be true.
However, this means that we have found a strictly better solution because
N−1∑
k=0
dk =
∑
k 6=i
k 6=j
d∗k + δ(d
∗
i + d
∗
j) >
N∑
k=1
d∗k,
resulting in a contradiction of the optimality assumption. Therefore, for [α/β]O <
γ[α/β]T , the unique optimal solution consists of uniform doses. The closed-form so-
lution, as given in (4.6), can be obtained by solving the quadratic equality constraint
γNdj
(
1 +
γdj
[α/β]O
)
= c.
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4.8.3 Proof of Lemma 4.4.1
Proof. We use a similar argument to the one given in Lemma 4.3.1. Let us suppose
an optimal solution is d∗i , for i = 0, 1, . . . , N − 1, under which the BEDO constraint
is not active. Let {Y˜ +i } be the result of delivering the optimal doses. Again, choose
the positive constants δ and ǫ in the same way as in Lemma 4.3.1. Then, for every i,
we are able to deliver di = d
∗
i + ǫ while ensuring the BEDO constraint is satisfied. Let
{Y +i } now be the result of delivering the di, for i = 0, 1, . . . , N − 1. We will show by
induction that Y +i < Y˜
+
i for every i. For the base case, we have
Y +0 = Y0 − BEDT (d0) < Y˜ +0
because d0 > d
∗
0. Suppose for the inductive step that Y
+
i < Y˜
+
i . Then, we have
Y +i+1 = F (Y
+
i )− BEDT (di+1)
< F (Y˜ +i )− BEDT (di+1)
= Y˜ +i+1,
where the inequality holds because the growth function F is strictly increasing as a
result of the φ(x) > 0 assumption. The induction is complete, and we have shown that
Y +N−1 < Y˜
+
N−1. This is a contradiction of the optimality assumption.
4.8.4 Proof of Lemma 4.4.2
Proof. Since φ(x) > 0 for all x, the rate of change of the number of tumor cells is
positive. Thus, assuming no delivered radiation, the number of cells is strictly increasing
due to repopulation. Now, given Y +i < Y˜
+
i , it is clear that Y
−
i+1 < Y˜
−
i+1. And after
applying radiation, we also have Y +i+1 < Y˜
+
i+1. The lemma follows by induction.
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4.8.5 Proof of Theorem 4.4.3
Proof. Suppose that an optimal solution to the fractionation problem with repopulation
is the sequence of doses d∗0, d
∗
1, . . . , d
∗
N−1, resulting in the sequence Y˜
+
0 , Y˜
+
1 , . . . , Y˜
+
N−1.
We assume here that d∗i > 0 and d
∗
j > 0 for some i and j such that i < j. Consider
another sequence d0, d1, . . . , dN−1 that satisfies dk = d∗k for k 6= i and k 6= j, which
results in the sequence Y +0 , Y
+
1 , . . . , Y
+
N−1. We will first show that if Y
+
i > Y˜
+
i (or,
equivalently, di > d
∗
i ), then Y
+
j ≤ Y˜ +j + BED∗T − BEDT , where BED∗T and BEDT
are the total BED in the tumor resulting from delivering {d∗k} and {dk}, respectively.
Before delivering the dose di, the same sequences of doses were applied; this means
Y −i = Y˜
−
i . Now, Y
+
i = Y
−
i − BEDT (di) and Y˜ +i = Y˜ −i − BEDT (d∗i ), implying that
Y +i − Y˜ +i = BEDT (d∗i )−BEDT (di). Since φ(x) is non-increasing as a function of x, we
have that
Y −j − Y˜ −j ≤ BEDT (d∗i )− BEDT (di). (4.17)
Note that BED(d∗i ) > BED(di) because of the initial condition Y
+
i > Y˜
+
i . Then, we
have
Y +j = Y
−
j − BEDT (dj)
= Y −j − BEDT (dj) + Y˜ +j − (Y˜ −j − BEDT (d∗j))
= Y˜ +j + (Y
−
j − Y˜ −j ) + BEDT (d∗j)− BEDT (dj)
≤ Y˜ +j + BEDT (d∗i )− BEDT (di) + BEDT (d∗j)− BED(dj)
= Y˜ +j + BED
∗
T − BEDT , (4.18)
where the inequality is due to (4.17).
Suppose that [α/β]O ≥ γ[α/β]T and that there exists i < j such that d∗i > 0 and
d∗j > 0. We set di = 0 and dj = d
∗
j + δ, where δ is a positive constant that enforces the
BED equality constraint for the OAR. Then, we find, as done using exactly the same
argument in the proof of Theorem 4.3.2, that BED∗T < BEDT . Since di = 0 and d
∗
i > 0
imply that Y +i > Y˜
+
i , we have from (4.18) that Y
+
j < Y˜
+
j . Using Lemma 4.4.2, we
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conclude that Y +N−1 < Y˜
+
N−1, so that we have found a strictly better solution than the
supposed optimal one. Thus, if [α/β]O ≥ γ[α/β]T , the optimal solution is to deliver a
single dose, as in Theorem 4.3.2.
Suppose [α/β]O < γ[α/β]T and ∃i < j such that d∗i > d∗j . Setting di = dj =
δ
(
d∗i+d
∗
j
2
)
so that δ ensures the BED constraint in the OAR. Again, we use the same
argument in Theorem 4.3.2 and conclude that BED∗T < BEDT . Since di < d
∗
i , we have
Y +i > Y˜
+
i . From (4.18), we conclude Y
+
j < Y˜
+
j . This means that Y
+
N−1 < Y˜
+
N−1 due to
Lemma 4.4.2. Thus, we have found a strictly better solution than the supposed optimal
one. For [α/β]O < γ[α/β]T then, the optimal doses must increase over the course of
treatment, i.e., d∗0 ≤ d∗1 ≤ . . . ≤ d∗N−1.
4.8.6 Proof of Theorem 4.4.4
Proof. We want to solve the optimization problem
maximize
N∈N
N−1∑
k=0
d∗k
(
1 +
d∗k
[α/β]T
)
− 1
αT
(N − 1)ρ, (4.19)
where d∗k for k = 0, 1, . . . , N − 1 is an optimal solution to (4.4). If [α/β]O ≥ γ[α/β]T ,
from Theorem 4.3.2, it is optimal to deliver a single dose on one day. Thus, the first
term in (4.19) is independent of N , and maximizing the second term results in N∗ = 1.
For the case when [α/β]O < γ[α/β]T , we first show that the objective in (4.19) is strictly
concave and eventually decreases as a function of N . Using the expression for d∗j given
in Theorem 4.3.2 and carrying out basic algebra, we find that the first term in (4.19)
representing the BED in the tumor satisfies
BEDT =
N−1∑
k=0
d∗k
(
1 +
d∗k
[α/β]T
)
B
αT
=
√
N2 + 2AN − B
αT
N + E,
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where A = 2c2
[α/β]O
, B = αT [α/β]O
2γ
(
1− [α/β]O
γ[α/β]T
)
, and E = [α/β]Oc2
γ2[α/β]T
. We want to show that
the objective (4.19) is concave in N for any N ∈ [0,∞). The domain [0,∞) is convex
as desired. Now, we compute the first and second derivative with respect to N of this
objective. After some algebra, we obtain the equations
d
dN
[
BEDT − 1
αT
(N − 1)ρ
]
=
B
αT
(
N + A√
(N + A)2 − A2 − 1
)
− ρ
αT
(4.20)
and
d2
d2N
[
BEDT − 1
αT
(N − 1)ρ
]
= − A
2B
αT (N2 + 2AN)
3/2
.
Note that A > 0, and since [α/β]O < γ[α/β]T , B > 0 is also true. Thus, the second
derivative above is strictly negative for all N ∈ [0,∞); this implies that the objective
is strictly concave. As N grows large, the first term in (4.20) approaches 0. Hence, the
first derivative eventually becomes strictly negative due to the repopulation term, which
means that the objective is a decreasing function for large enough N . Maximizing a
strictly concave function that eventually decreases results in a unique optimum over
the interval [0,∞). Now, we set the derivative (4.20) equal to 0 and solve for N . The
result is
Nc = A
√ (ρ+B)2
ρ (ρ+ 2B)
− 1
 .
Due to the concavity property of the objective, the additional constraint that N is a
natural number means that the optimum N∗ is either ⌊Nc⌋ or ⌈Nc⌉, whichever results
in a larger objective value. The only exception is when Nc < 1, in which case N
∗ = 1
since N∗ cannot be 0.
4.8.7 Proof of Theorem 4.4.5
Proof. When [α/β]O ≥ γ[α/β]T , we already know from Theorem 4.4.3 that N∗ = 1
and thus the optimal number of fractions is finite. We now give the proof for the case
when [α/β]O < γ[α/β]T . For a fixed N , we assume d
∗
0, d
∗
1, . . . , d
∗
N−1 is the sequence of
127
optimal dose fractions resulting from minimizing the logarithm version of the expected
number of cells Y ∗N−1 subject to the BED constraint in the OAR. From the equation
dy/dt = φ(exp(αTy(t)))/αT , the assumption φ(x) > r implies dy/dt > r
′/αT for some
other constant r′ > 0. The function mapping Y + to Y − as a result of repopulation
satisfies
F (Y +) > Y + +
r′
αT
.
Now, since F is applied N − 1 times, we can bound below Y +N−1:
Y +N−1 > −BED∗T +
1
αT
(N − 1)r′
where BED∗T is the BED in the tumor resulting from delivering the doses d
∗
0, d
∗
1, . . . , d
∗
N−1.
From Theorem 4.3.2, we know that when [α/β]O < γ[α/β]T , uniformly distributed
doses maximize BEDT subject to the constraint on BEDO. Let B˜EDT represent the
BED in the tumor resulting from delivering these uniformly distributed doses. Then,
BED∗T ≤ B˜EDT and we have
Y +N−1 > −BED∗T +
1
αT
(N − 1)r′ ≥ −B˜EDT + 1
αT
(N − 1)r′.
Using equation (4.20) from the proof of Theorem 4.4.4, we have
d
dN
[
−B˜EDT + 1
αT
(N − 1)r′
]
= − B
αT
(
N + A√
(N + A)2 −A2 − 1
)
+
r′
αT
.
Since the first derivative above eventually stays positive for large enough N , Y +N−1
approaches infinity as N →∞. Thus, the optimal number of dose fractions N∗ cannot
be infinite.
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Chapter 5
Optimal fractionation for
continuous dose rate treatment
protocols
5.1 Introduction
We analyzed in the previous chapter the optimal fractionation scheme in the presence
of tumor repopulation. However, the model used was reasonable only for conventional
external beam radiation therapy, where there is plenty of time in between fractions. In-
complete repair of sublethal damage in cells becomes an important factor for treatment
modalities such as brachytherapy, where a continuous dose is emitted from implanted
seeds in the patient. In this chapter, we model this repair effect in addition to tumor
repopulation and generalize the methods in the previous chapter to the case where a
continuous dose rate d(t) is delivered instead of individual dose fractions. It may be
difficult for the reader to follow the arguments in this chapter without familiarity of
the model, formulation, and results from Chapter 4.
As before, we would like to minimize the expected number of tumor cells at the end
of treatment such that the BED in the OAR is constrained by an upper limit. The only
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difference is that incomplete sublethal damage repair needs to be taken into account due
to the continuous nature of the radiation dose. In this chapter, we derive an ordinary
differential equation describing the behavior of the number of tumor cells at any point
during treatment. This equation incorporates the effect of tumor growth, incomplete
sublethal damage repair, and radiation dose. Although the same differential equation
and a similar formulation is presented in [87], we hope that the derivation in this chapter
is insightful and sheds new perspective. The model and formulation can be the basis
for further research, e.g., determining the effect of accelerated tumor repopulation for
modalities such as brachytherapy. In a related paper [5], the effect of exponential tumor
repopulation and sublethal damage repair on optimal fractionation is analyzed for the
case of discrete radiation dose fractions. However, our main focus in this chapter is on
continuous dose rate treatment protocols and on general tumor growth characteristics.
In Section 5.2, we describe the model and formulation, including extensions of the
tumor dynamics and BED model in the continuous case. In Section 5.3, we show
that the presented continuous model is consistent with the discrete-time version in the
previous chapter. In Section 5.4, we summarize and discuss possibilities for future
research.
5.2 Model and formulation
In this section, we discuss the model and formulation for a continuous dose rate treat-
ment protocol. First, we describe an LQ model that includes sublethal damage repair.
Next, we develop a single differential equation that models the tumor dynamics. Then,
we extend the BED model to the continuous case; we use this extended BED model
to assert a constraint on the BED in the OAR. Finally, we summarize the problem
formulation of minimizing the expected number of tumor cells at the end of treatment
subject to an upper limit on the BED in the OAR.
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5.2.1 LQ model with incomplete sublethal damage repair
We define T to be the total treatment time (analogous to the number of dose fractions
N in the previous chapter). Assuming that the dose rate d(t) is delivered over the time
interval [0, T ], it is tempting to describe the cell survival fraction with the equation
S = exp
(
−
∫ T
0
(αd(t) + βd2(t)) dt
)
. (5.1)
However, this equation does not make sense for radiation dose delivered over very small
intervals of time. For example, suppose that a total dose d is uniformly delivered over
an interval of length δ1 or, alternatively, of length δ2. If 0 < δ1 < δ2, the above equation
(5.1) would suggest that the survival fraction is smaller when dose is delivered over the
interval of length δ1. Assuming both δ1 and δ2 are very small intervals of time, this does
not make intuitive sense. This apparent difficulty can be overcome by using a more
general version of the LQ model that includes incomplete sublethal damage repair.
Incomplete repair can be incorporated into the LQ model by introducing the dose
protraction factor G as done in [8, 67]. The surviving fraction including incomplete
repair of sublethal damage is given by
S = exp(−(αD +GβD2)), (5.2)
where D =
∫ T
0
d(t)dt and
G =
2
D2
∫ T
0
∫ T
0
d(t)d(τ)K(t, τ) dτ dt
=
2
D2
∫ T
0
d(t)e(t) dt,
where
e(t) =
∫ T
0
d(τ)K(t, τ) dτ (5.3)
and K(t, τ) is a suitable kernel function. We assume that the sublethal damage decays
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exponentially, i.e., that the kernel K(t, τ) takes the form
K(t, τ) = u(t− τ) exp(−(t− τ)/τr),
where u(·) is the unit step function and τr is the tissue repair time for sublethal damage.
Now, for very small values of the repair time τr, changes in the dose rate d(t) over
small instants of time can make a big difference in the survival fraction. Indeed, as
τr → 0, it can be seen that the survival fraction is described by Equation (5.1). In
our initial discussion, we provided an example of how dose variations over a small time
interval can result in a large effect on the survival fraction. A large τr, on the other
hand, results in little effect for these dose variations. Thus, based on the repair time
parameter τr, this model allows the choice of the right tradeoff for the particular cell
tissue under consideration.
5.2.2 Tumor dynamics
In this subsection, we derive a differential equation that describes the dynamics of the
number of tumor cells x(t) over the time interval [0, T ], where T is the total treatment
time. It includes general tumor growth characteristics and incomplete sublethal dam-
age repair due to continuous radiation dose administered. Assume that the dose rate
d(t) is delivered over the time interval [0, T ]. Let φ(x(t)) be the instantaneous tumor
proliferation rate. Given x(t), we will derive the resulting number of cells after a very
small unit of time δ > 0. This will lead us to the differential equation representation of
the tumor dynamics.
Based on Equation (5.2), the survival fraction in the time interval [t, t+ δ] will be
exp
(
−
∫ t+δ
t
(αTd(t) + 2βTd(t)e(t)) dt
)
= exp
(
−αT
∫ t+δ
t
d(t)
(
1 +
2eT (t)
[α/β]T
)
dt
)
,
where eT (t) is defined using Equation (5.3) with the repair time for the tumor, τ
1
r .
For small δ, the effect of tumor repopulation results in x(t + δ) ≈ x(t) + δφ(x(t))x(t).
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Including the effect of radiation, we have that
x(t + δ) ≈
(
x(t) + δφ(x(t))x(t)
)
exp
(
−αT
∫ t+δ
t
d(t)
(
1 +
2eT (t)
[α/β]T
)
dt
)
≈
(
x(t) + δφ(x(t))x(t)
)
exp
(
−δαT
(
1 +
2eT (t)
[α/β]T
))
≈
(
x(t) + δφ(x(t))x(t)
)(
1− δαTd(t)
(
1 +
2eT (t)
[α/β]T
))
, (5.4)
where in (5.4) we use a Taylor series approximation. Rearranging the above equation,
we have that
1
x(t)
x(t + δ)− x(t)
δ
≈ φ(x(t))− αTd(t)
(
1 +
2eT (t)
[α/β]T
)
.
Thus, as δ approaches 0 in the limit, we arrive at the differential equation
1
x(t)
dx(t)
dt
= φ(x(t))− αTd(t)
(
1 +
2eT (t)
[α/β]T
)
. (5.5)
The first term on the right-hand side of the above equation represents the increase in
tumor growth due to repopulation, and the second term is the decrease due to radiation
delivery. We can also write the above differential equation in terms of y(t), which is
related to the x(t) through the definition y(t) = ln(x(t))/αT :
dy(t)
dt
=
1
αT
φ(exp(αTy(t)))− d(t)
(
1 +
2eT (t)
[α/β]T
)
.
The dynamics of tumor growth during therapy now is modeled. We would like to
constrain BED in the OAR in the problem formulation. To do this, we proceed to derive
the BED model including incomplete sublethal damage repair when using continuous
radiation delivery.
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5.2.3 BED model for continuous dose rate
We include the dose protraction factor G in the following derivation of the BED. We
denote BED(d, t′) to be the total BED resulting from delivering the dose rate d(t) in
the time interval [0, t′]. Recall from Chapter 4 that the BED related to the survival
fraction S through the equation BED = − ln(S)/α. Using this relation, we find
BED(d, t′) =
∫ t′
0
d(t)
(
1 +
2e(t)
[α/β]
)
dt.
Using the above relation, we define BEDO(d, t
′) as the BED in the OAR with parameter
[α/β]O and the sparing factor γ. We also define (for convenience in notation) the total
BED in the OAR, BEDO from delivering the dose rate d(t) over the time interval [0, T ]:
BEDO = BEDO(d, T ) =
∫ T
0
γd(t)
(
1 +
2γeO(t)
[α/β]O
)
dt,
where eO(t) is defined using the equation (5.3) with the repair time for the OAR, τ
2
r .
As done in Chapter 4, we assert the constraint BEDO ≤ c in the optimization to ensure
a given level of NTCP.
5.2.4 Problem formulation
We formulate the optimization problem as
minimize
d(t)≥0
X+N−1 s.t. BEDO ≤ c,
where X+N−1 is the expected number of tumor cells after radiation treatment and c
is an appropriate constant. The dynamics of the tumor throughout the treatment
are governed by the differential equation (5.5). Though we do not provide a solution
method to solve this formulation, we discuss possible methods later in the chapter.
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Figure 5-1: Illustration of the discrete-time setup using the continuous-time model. The
repair time, treatment time, and time between fractions are τr,τt, and τf respectively.
5.3 Consistency with discrete-time model
In this section, we show that the continuous time model derived thus far is consistent
with the discrete time version in Chapter 4. In particular, given that τt is the delivery
time of a single dose fraction and τf is the time between dose fractions (Figure 5-1), we
show that the discrete time model in Chapter 4 is a good approximation if τt ≪ τr ≪ τf .
That is, if the delivery time of one dose is fast enough in comparison to tissue repair
times and if there is enough time between treatments for repair of sublethal damage, a
discrete time model can be used.
We will first consider the case where a single dose of radiation is delivered. Suppose
that a total dose of dk is delivered uniformly over the interval [k, k+ τt], i.e., d(t) equals
dk/τt for k ≤ t ≤ k + τt and 0 otherwise. We would like to now compute the resulting
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BED for this choice of d(t). The function e(t) is
e(t) =
∫ T
0
d(τ)u(t− τ) exp(−(t− τ)/τr) dτ
=
∫ t
k
dk
τt
exp(−(t− τ)/τr) dτ
≈
∫ t
k
dk
τt
dτ
=
dk
τt
(t− k) ,
where we modified the limits of integration due the definitions of d(t) and u(t) in the
second equality, and we assumed τt ≪ τr to obtain the approximation in the third
equation. Now we compute the BED:
BED =
∫ k+τt
k
d(t)
(
1 +
2e(t)
[α/β]
)
dt
≈
∫ k+τt
k
dk
τt
(
1 +
2dk/τt (t− k)
[α/β]
)
dt
= dk
(
1 +
dk
[α/β]
)
,
which is exactly the expression for BED for a single dose in the discrete time case.
Now we generalize the expression for BED for multiple radiation doses. Suppose
that N radiation doses d0, d1, . . . , dN−1 are delivered uniformly over time intervals of
length τt. Let the separation between each of the doses be τf (Figure 5-1). We will
assume τf ≈ 1 day; the analysis can be extended with the same arguments for any
τf . Thus, the kth dose dk is delivered in the time interval [k, k + τt], assuming time
in units of days. We assume that the repair time τr is much smaller than the time
between treatments τf , i.e. τr ≪ τf . In this case, note that exp(−(t− τ)/τr) ≈ 1 when
k ≤ τ ≤ k + τt and exp(−(t − τ)/τr) ≈ 0 when τ ≤ k − 1, assuming τt ≪ τr. We now
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compute the total BED:
BED =
∫ T
0
d(t)
(
1 +
2e(t)
[α/β]
)
dt
=
N−1∑
k=0
∫ k+τt
k
d(t)
(
1 +
2e(t)
[α/β]
)
dt
≈
N−1∑
k=0
∫ k+τt
k
d(t)
(
1 +
2
∫ t
k
d(τ) dτ
[α/β]
)
dt
=
N−1∑
k=0
dk
(
1 +
dk
[α/β]
)
, (5.6)
which is exactly the expression for BED in the discrete-time case.
Now, we would like to show that the continuous-time formulation is consistent with
the discrete-time one. For the discrete-time case in Chapter 4, tumor growth was
characterized by the differential equation
dy(t)
dt
=
1
αT
φ(exp(αTy(t)))
and at an integer time k, the radiation dose resulted in
y(k+) = y(k−)− dk
(
1 +
dk
[α/β]T
)
.
Let us again consider the single dose case in continuous-time. That is, let dk be uni-
formly delivered over the interval [k, k + τt]. Then,
y(t+ τt) ≈ y(t) + τt 1
αT
φ(exp(αTy(t)))− dk
(
1 +
dk
[α/β]T
)
,
which for very small treatment time τt approaches the equation (5.3) for the discrete-
time case. Furthermore, for k+τt ≤ t ≤ k+1, the continuous-time differential equation
consists only of the tumor repopulation term, and thus, matches the discrete-time
version. Finally, the BED constraint in the OAR (5.6) is also the same as in the discrete
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time formulation. We have thus shown that the tumor dynamics and the constraint in
the continuous-time formulation is consistent with the discrete-time case.
5.4 Discussion, conclusions, and future outlook
We have extended the formulation from the previous chapter to the case of a continuous
dose rate d(t) treatment protocol. Due to the interactions between radiation dose in
close instants of time, it was necessary to include incomplete sublethal damage repair
into the LQ model. The dynamics governing the number of tumor cells at any instant of
time was written as an ordinary differential equation. We showed that this continuous
time model and formulation was consistent with the discrete-time one in the previous
chapter. We do not claim that the model and formulation is novel because a similar
setup is found in [87]. However, we hope that the derivations shed new perspective into
the problem and it may serve as the basis for future work.
The solution method to solve the fractionation problem was not discussed in this
chapter. One possibility is to use a dynamic programming approach similar to the one
in the previous chapter. However, we need to consider a few additional issues. First,
the continuous nature of the optimal control requires discretization in time. Using a
fine discretization and Euler’s approximation for example, the differential equation in
this chapter can be converted to a state update equation similar to the one in the
previous chapter. Second, due to inclusion of the incomplete sublethal damage repair,
additional states eT (t) and eO(t) are required. Thus, the state of the system would
be captured by (eT (t), y(t), eO(t), z(t)), where z(t) is the cumulative BED in the OAR
over the time interval [0, t]. Yet, an exact dynamic programming approach may not
be computationally tractable. If, for example, each state variable is discretized into
100 units, we will have to evaluate 100 million states for each time instant. It may
be necessary to resort to approximate dynamic programming methods in this case.
Since we have a deterministic problem, an alternative approach could be to use general
gradient-based non-linear programming methods. The dimension of the gradient would
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be determined by how finely one discretizes over time. Of course, there are no convexity
properties in this problem and only a local optimum is guaranteed with these methods.
There is scope for future work in the choice of solution method for this fractionation
problem.
The presented model and formulation could be used to analyze the implications
of accelerated repopulation on optimal fractionation schemes for continuous dose rate
treatment protocols such as brachytherapy. A recent paper has validated that acceler-
ated repopulation exists in cervical cancer with relatively short onset time [29]. Given
that conventional treatment for cervical cancer is a combination of external beam radia-
tion therapy and low-dose rate brachytherapy [9], there is potential for further research
investigating alternative fractionation schemes that can result in improved treatment
for this disease site.
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Chapter 6
Conclusions
In this thesis, we studied dynamic optimization of fractionation schedules for radiation
therapy. In the first part, in Chapters 2 and 3, we considered varying the daily fraction
size based on geometrical information from imaging of the patient anatomy. Along with
characterizing properties of optimal policies, we found that adaptively varying the frac-
tion size can be beneficial. We substantiated this conclusion with results from prostate
patient datasets. For prostate cancer, the approaches are particularly beneficial because
of the high sensitivity of the tumor to radiation. We also suggested daily selection of
a treatment plan from a plan library in order to avoid daily QA procedures. Future
work could couple the two problems and simultaneously optimize the dose intensities
spatially and temporally.
In Chapters 4 and 5, we considered the effect of tumor repopulation on the optimal
fractionation schedule. We were motivated primarily by the accelerated repopulation
observed towards the end of radiation treatment, which is believed to play a role in
treatment failure for some tumor sites. A dynamic programming framework was devel-
oped to determine the optimal fractionation scheme based on a model of cell kill due to
radiation and tumor growth in between treatment days. We proved that the optimal
dose fractions are increasing over time and suggested larger dose fractions later in the
treatment to compensate for the increased tumor proliferation.
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While much work has been done on the algorithmic aspects of adaptive fractionation,
there is still a need to quantify the benefit for specific disease sites. The work in
Chapter 3 found significant benefit for prostate cancer, particularly because of the
high sensitivity of the tumor to radiation. We would also expect significant benefit for
other tumors with high sensitivity. In Chapter 3, we also selected from a library of
two treatments plans: one with a small margin and one with a large one. However,
an interesting approach would be to generate the plan library itself by an optimization
procedure. The question of interest would be: Given some knowledge of the uncertainty
in motion, how can we generate two treatment plans? At first glance, this problem seems
to have a combinatorial nature and thus difficult to solve. The advantage is that this
type of selection from a plan library procedure and also adaptive fractionation does
not have the drawback of daily QA procedures. For adaptive fractionation, the beam
intensities simply need to be scaled up. For selection from a plan library, the treatment
plans would be pre-approved prior to the start of treatment.
The two parts of this thesis, adaptive fractionation and optimal fractionation in
the presence of tumor repopulation, were developed independently. But, an interesting
consideration for future investigation could be to assume that the normal tissue spar-
ing factor γ from Chapter 4 varies from day to day. This is similar to the adaptive
fractionation work except that tumor repopulation is included. Including more realistic
assumptions, such the repair effect from Chapter 5 and tumor re-oxygenation, into the
analysis could also be useful.
In Chapter 4, we looked into the effect of tumor repopulation on how the dose
should be varied temporally. A question of future interest is whether the dose should
be varied both spatially and temporally assuming tumor repopulation or more generally
a biological model. For example, it may be the case the a different dose distribution is
optimal on each treatment day even when no organ motion is assumed and no imaging
information is used. The work in [40] has looked into adapting spatio-temporally using
biological-based imaging. Yet, it is still of interest to understand the biological modeling
assumptions which lead to different treatment plans from day to day.
142
In the general area of optimal fractionation for cancer treatment, a vast amount
of work has been done individually for radiation therapy and chemotherapy. Yet, far
fewer studies have considered the potential of optimal scheduling of combined radiation
and chemotherapy [22, 24, 31, 36, 43, 72, 90]. For certain cancers especially advanced
and metastasized ones, chemotherapy (treatment through anti-cancer drugs) is more
effective than radiation therapy. However, targeted tumor cells generally become more
resistant over time, and increasing the drug dose cannot always be a viable option
because it can cause systemic damage to the patient. There is significant potential
for improving treatment by modeling and optimizing the complex interactions between
anti-cancer drugs and radiation dose.
Biologically guided radiation therapy, where patient-specific treatment is achieved
through both modeling and imaging advancements, provides an exciting possibility for
the future. A survey and positive outlook towards clinical implementation is provided
in [73]. With advancements in PET imaging techniques that can measure for example
tumor proliferation rates during the course of therapy [3], the opportunity to adapt
rather than use models becomes a possibility. In terms of the physical dose, technology
and optimization techniques have enabled precise delivery to the tumor. Advances in
technology have enabled new modalities such as volumetric arc therapy (VMAT), and
there are challenges to overcome in the optimization of treatment planning. Still, it
is fair to say that the potential for drastic changes and improvements in treatment
planning exists more so when incorporating biological information. Understanding the
biological processes at the molecular level together with advancements in imaging can
enable effective treatment planning in the future.
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